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I. INTRODUCTION
Therapeutic agents which are capable of specifically targeting a pathogen but which
are not accompanied by serious dose-limiting toxicities, continue to be of great interest to
both the chemical and pharmaceutical communities.In order to induce a desirable
chemical response, many drugs target a specific enzyme, receptor, or ion channel in
which the mode of action may not be completely understood.1 Designing drugs which
are capable of binding to a particular protein can be further complicated, due to the
structural complexity of the protein target. Hence, there have been concerted efforts to
develop drugs which would inhibit a disease-causing protein by targeting its precursor
messenger RNA (mRNA), since it is believed that mRNA may be a more vulnerable link
in the genetic cycle.2There appear to be considerable advantages in developing
therapeutic agents which manipulate genetic expression at the level of mRNA translation,
as opposed to specifically targeting a protein. Perhaps the most striking of these is
efficiency, since each mRNA gives rise to multiple protein copies. Consequently, this
strategy has stimulated considerable interest in the possibility of utilizing nucleic acids or
modified oligonucleotides as potential therapeutic agents, in order to bring to fruition the
promise of the antisense concept.
The applicability of this method was first successfully demonstrated by Zamecnik
and Stephenson,3 in which Rous sarcoma virus 35S RNA (the sense strand) was targeted
with a tridecamer complementary to 13 nucleotides of the 3'- and 5'-reiterated terminal
sequences of Rous sarcoma virus 35S RNA (the antisense agent), thereby inhibiting virus
replication. The results of their early biological experiments suggested that antisense2
oligonucleotides were finding their way into cells, because they had affected the functions
of viral nucleic acids in the cytosol.4 This was further suggested in experiments with
radiolabelled oligonucleotides and their derivatives, in which the radioactive material had
accumulated in the cell nuclei and cytoplasm.5,6,7 Intracellular localization of the
oligonucleotides was demonstrated in one of these experiments, via reactive alkylating
oligonucleotide derivatives.5 It was found that oligothymidylates reacted with the desired
cellular RNA target (polyA).It was further suggested that complex formation was a
necessary condition in order for reaction to occur, since modification was found to be
temperature dependent. An interaction with cellular DNA was also observed in these
experiments, and the specificity of this reaction suggested that at least a part of the
process was sequence-specific.
Kinetic studies have suggested that oligonucleotides are taken up in cells in a
saturable manner, and that the process is hampered by temperature decrease and by
inhibitors of endocytosis, suggesting an endocytotic mechanism of uptake.8 The
aforementioned studies suggest that there are mechanisms (possibly endocytosis) which
enable cells to internalize oligonucleotides, although the efficiency of such uptake is quite
poor. To improve it, one can either attempt to employ a more efficient cellular uptake
mechanism, or to develop artificial approaches in order to bypass the natural
mechanisms.4
An antisense agent should satisfy three basic requirements if it is to effectively
suppress gene expression.2 First and foremost the drug should be sequence-specific, in
order to selectively bind the target mRNA molecule. Secondly, the agent should be stable
in vivo. Due to the susceptibility of native oligonucleotides toward nuclease degradation,
unmodified nucleic acids do not appear to be suitable therapeutic targets. The ideal
candidate therefore appears to be an oligonucleotide analogue which possesses sufficient
stability toward nuclease degradation, so as not to compromise its efficacy. Lastly, the
desired compound should be water soluble, but should also be capable of cellular uptake.3
Several extensive reviews have recently described the various types of antisense
oligonucleotides which have been synthesized and tested with these criteria in
mind.1,2,9,10,11,12 This thesis will not discuss in great detail the various approaches
which have been investigated to date, but will instead focus on a class of analogues in
which the ribose and phosphodiester moieties have been replaced by an uncharged acyclic
backbone. Uncharged analogues appear to be particularly attractive in regard to cell
membrane permeation, and have been reported to possess improved cellular uptake
properties.13,14
The pioneering work in the development of these modified acyclic analogues was
that of Pitha and Pitha, who investigated poly(Nl- vinyluracil) 1, poly(N1-vinylcytosine)
2 and related species.15 Poly(N1-vinyluracil) was prepared by radical polymerization of
N1- vinyl -4- ethoxy -2- pyrimidinone 3 followed by acid catalyzed hydrolysis of the
resulting polymer.16 This method was found to be superior to the direct polymerization
of N1 -vinyluracil, although this procedure also proved to be successful.Poly (N1-
vinylcytosine) containing a small amount of uracil residues was similarly prepared by
reaction of poly(N1-vinyl -4-ethoxy-2-pyrimidinone) 3 with ammonia.17 The interaction
of 1 with adenine derivatives and the interaction of 2 with polyguanylic acid were
thoroughly investigated. While the observed binding interactions of poly(N1-vinyluracil)
to adenosine derivatives were found to be weaker than analogous binding by poly U, the
interaction of poly(N1-vinylcytosine) with poly G was found to form complexes with
high stability. The ability of these vinylogous analogues to form hydrogen-bonded
complexes with complementary oligonucleotides is remarkable given the atactic nature of
the backbone and due to the improper spacing of bases along the analogue backbone, as
illustrated in Figure 1.It is unlikely that heteropolymers, if they can be prepared, will
show highly sequence specific binding, due to the probable lack of uniform structure in
the analogue-nucleic acid complex.O NH2
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Figure 1. Interaction of Poly(N I-vinylcytosine) with Poly G
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There are many examples of modified nucleic acids in the literature which do not
employ the use of a stereochemically defined backbone and, consequently, diastereomeric
mixtures are generated during their chemical syntheses. Since each diastereomer may
have its own distinct binding affinity for its complementary nucleic acid sequence, it is
advantageous to develop oligomers possessing either a diastereomerically pure or an
achiral backbone. This ensures that the agent maintains a uniform binding constant to its
target sequence, thereby maximizing its efficacy. The earliest example in the literature in
which this stereochemical issue is considered is that by Jones and coworkers, who
address the importance of obtaining a polypeptide of known stereochemistry in their
uncharged, acyclic class of peptide analogues.18 This is exemplified in the resolution of5
DL-B-(thymin- l-ypalanine 4, prior to polymerization. The resulting optically active
amino acid polymers showed no evidence of base stacking however, or of interaction
with poly A. Jones and coworkers suggest that this may be attributable to the low
average molecular weight of the poly-B-(thymin-l-y1) alanines 5, which in the optically
pure D-series was approximately ten residues long. Note as illustrated in Figure 2, that
due to the spacing of the bases on the backbone, only every other base is properly
positioned for binding a complementary nucleic acid.
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Figure 2. Interaction of Poly-0-(thymin- 1-y1) alanine with Poly A6
One feature common to both these early investigations is that they rely on
polymerization reactions. Few examples in the literature to date have investigated
systematic approaches toward planning and constructing these acyclic analogues. This is
a key consideration if these analogues are to have significant therapeutic utility, since the
ultimate future objective is to develop an analogue oligomer capable of sequence-specific
binding to a particular gene message or complementary viral sequence. Developing a
method which would allow systematic construction of oligomers was therefore one of the
central concerns in our research, and was a notable consideration in choosing the proper
oligonucleotide analogue backbone. We proposed that this requirement could be satisfied
by utilizing a backbone whose subunits are linked by amide or related linkages, whereby
standard coupling procedures and, ultimately, solid-phase synthesis could be employed.
The key questions to be answered were those pertaining to the necessary length of
analogue backbone subunits and the mode of attachment of heterocyclic bases along the
polyamide backbone.
Preliminary studies were performed by Prof. Dwight D. Weller in collaboration with
Dr. James Summerton of Antivirals, Inc. using space filling (CPK) models to analyze the
association of acyclic analogues and complementary nucleic acids. The feasibility of
replacing the sugar-phosphate backbone of the nucleic acids with a polyamide-type
backbone has been further investigated by Prof. Weller and Dr. Wilma Olson of Rutgers
University, using molecular modeling techniques to examine the ability of the acyclic
backbone to adopt low energy conformations that conform to the nucleic acid A- and B-
form helices.19
In brief, the modeling studies concluded that the bases should not be directly attached
to the polyamide backbone. A methylene spacer between the base and the attachment site
was found to alleviate unfavorable nonbonding interactions between the base and the
backbone, while significantly increasing the coplanarity of complementary bases in the
putative analogue/nucleic acid duplex. The optimum length of the monomeric subunit7
appears to be five or six atoms including the terminal amine and carboxyl group of each
subunit. Several acyclic backbone possibilities of the amide type (nylons, polyurethanes,
polypeptides) were considered, and we have thus far only reported the synthesis and
oligomerization of hexamers derived from amino acid analogues 6 and 7.20 Due to
problems associated with the solubility and purification of these oligomers in organic
solvents, we have addressed the need for more efficient assembly of short oligomers via
solid-phase synthesis (vida infra)21,22
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The modeling studies further suggested that two of the more promising backbone
types appear to be the polyurethanes 8 (due to their relatively low strain energy) and the
polypeptides 9 (due in part, to their ability to adopt a low energy helical conformation
incorporating an intermolecular 1,7-hydrogen bond).19 The interactions of 8 and 9 with
poly dG are shown in Figures 3 and 4, respectively. Of particular interest is the effect of
stereogenicity on the ability of these two classes of analogues to pair with complementary
RNA or DNA, since the modeling studies suggested a stereochemical preference with
certain backbone types.Consequently we undertook a program to first develop
stereochemically pure homooligomers containing only cytosine heterocyclic bases.
Relatively shorter oligomers could then be utilized during biophysical testing procedures
(due to the additional hydrogen bond in the GC base pair, as previously demonstrated in8
the binding studies of the morpholine-derived oligomers),23 which would simplify
matters considerably in regard to chemical synthesis.
NH2
NI
0 Nj
I
CH2
,..I,,,0
ril
H
n
8
Figure 3. Interaction of Polyurethane 8 with Poly dG9
Figure 4. Interaction of Polypeptide 9 with Poly dG
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We envisioned that compounds 10 and 12 (and their enantiomers, 11 and 13) could
be conveniently synthesized from (L)-serine { and (D)-serine, respectively).Each
configuration could thereby be obtained in optically pure form, so as to satisfactorily
address the stereochemical ramifications, and standard peptide coupling procedures
would enable the systematic assembly of subunits. These activated subunits could then
be assembled via solid-phase synthesis, to afford the urethane-derived oligomers 14 and
15, and the peptide-based oligomers 16 and 17. Should any of the proposed backbone
types prove to pair with its nucleic acid complement, this methodology could be easily
extended to the remaining heterocyclic bases (G, A, and T), to allow the synthesis of
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At the outset of this project, there were no examples in the literature in which an
analogue (possessing either an achiral or a stereochemically defined backbone) was
assembled in a systematic fashion and which was reportedly capable of sequence-specific
pairing with its nucleic acid complement. Since then, however, one noteworthy class of
compounds employing an achiral backbone, 18, has appeared in the literature.24 These
so-called peptide nucleic acids (PNAs) reportedly have strong binding affinity to
complementary nucleic acids,25,26 and are also capable of inducing strand displacement
of one of the two strands in double-stranded DNA, under low salt conditions.24,27 Other
recent publications by Nielsen and coworkers have followed,28 including an account in
which the sequence-specific inhibition of DNA restriction enzyme cleavage was obtained
with the complementary PNA.29 These results indicate that PNAs can be utilized as
sequence-specific blockers of DNA recognizing proteins, and further suggest the
applicability of using modified, acyclic analogues as code blockers.
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II. RESULTS AND DISCUSSION
A. Development of a Universal Solid-Support
Previous difficulties associated with characterization of fully deprotected hexamers 6
and 7 by mass spectrometry, coupled with the fact that most prexisting solid-phase
synthetic methods for nucleic acids entail the ammonolytic liberation of the base-protected
species from the resin, led to a search for a new method to enable incorporation of a
cleavable anchor (which would be suitable for the removal of fully protected analogue
oligomers from solid supports).Universal solid-support 19 was consequently
developed, and has proven to be an efficient and versatile means for the solid-phase
assembly of uncharged nucleic acid analogue subunits.30
H
SSAN
O jojs-N-- MMTr
O
The strategy for the synthesis of 19 is outlined in Scheme I. The starting material
utilized in the synthesis of 19 was 2-(2-aminoethoxy)ethanol 20. Reaction of 20 with
monomethoxytrityl chloride in pyridine, resulted in 75% yield of the protected amine 21.
This protected amine was then stirred with FMOC-proline and 1-(3-dimethylamino
propyl)- 3- ethylcarbodiimide methiodide in pyridine, to afford the proline ester product 22
in 74% yield. The FMOC-protected amino acid ester 22 was then dissolved in DMF
containing triethylamine and heated gently to facilitate FMOC removal. To this amine-13
containing solution was added active ester 23, resulting in the formation of dipeptide
product 24 in 80% yield.The synthesis and characterization of compound 23 is
discussed elsewhere.22 Subsequent reaction of the free hydroxyl of 24 with bis(p-
nitrophenyl) carbonate in the presence of triethylamine in DMF provided 79% yield of
mixed carbonate 25. Attachment of this cleavable anchor to aminomethyl polystyrene
gave rise to universal solid-support 19. The loading capacity of resin 19 was quantitated
via monomethoxytrityl assay at 476 nm in 20% trifluoroacetic acid/chloroform following
protecting group removal, and was found to be 290 mmol/g of dry resin.
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B. Preparation of Activated Subunits
With universal support 19 at our disposal, attention was directed toward the
synthesis, oligomerization, and biophysical evaluation of two novel classes of
stereochemically defined nucleic acid analogues, specifically those derived from the
nonisolable five-atom carbonic acid 26 (and its enantiomer), and those derived from the
modified six-atom alanylglycine 27 (and its enantiomer).I will focus first on the
synthesis of the urethane-derived hexamer 28 (and 29), and will later describe
subsequent efforts toward the peptide-derived class of analogues 16 (and 17), both
conveniently available from a common synthetic intermediate, compound 30 (and its
enantiomer).
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The strategy for synthesis of intermediate 30 and its conversion to activated
monomer 10 is outlined in Scheme II.(R)-N-t-butoxycarbony1-2,2-dimethy1-4-
hydroxymethyl-1,3-oxazoline31, was prepared from (L)-serine in the usual
manner.31,32 Optical purity of alcohol 31 was established by reacting separately with
each configuration of Mosher's reagent,33 and analyzing the corresponding diastereomer
via high resolution NMR spectroscopy. Analysis of the 1H spectra of diastereomeric
esters 32 and 33 revealed noticeable changes in chemical shift of two of the five
oxazoline ring/exocyclic methylene protons, and neither diastereomer was found to be
contaminated with the other, within the limits of detection (.1%).
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Reaction of 31 with tosyl chloride and N-methylimidazole in methylene chloride
proceeded smoothly to provide pure tosylate, which when reacted with the potassium salt
of cytosine in dimethyl sulfoxide gave rise to alkylated species 30 in 72% yield.
Acylation of cytosine with the morpholine-derived ionizable protecting group in
pyridine,16,17 proceeded smoothly to provide 86% yield of fully protected hemiaminal
34. An ionizable protecting group for cytosine was desirable to enable purification of the
protected hexamers via ion-exchange chromatography. Following cleavage of both t-
BOC and hemiaminal protecting groups, the resulting amine was tritylated to provide the17
desired alcohol 35 in 60% yield.Reaction of alcohol 35 with bis-p-nitrophenyl
carbonate and triethylamine in methylene chloride served both as a method to elongate the
backbone by one carbon, and to activate the carboxyl terminus as the p-nitrophenyl ester,
affording the activated monomer 10 in 98% yield. Enantiomeric carbonate 11 was
similarly obtained following the same sequence of synthetic transformations as described
in the synthesis of 10, with the exception that D-serine was substituted for L-serine as
starting material. Optical purity of 11 was confirmed by comparing the rotation values of
10 and 11, which were found to be of equal and opposite magnitude.
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The synthesis of the activated alanylglycine subunit 12 (and its enantiomer, 13) was
similarly undertaken and is outlined in Scheme III, in which intermediate 30 (and its
enantiomer) was again utilized as the starting material.Acylation of 30 with t-
butylbenzoyl chloride in pyridine resulted in 75% yield of fully protected hemiaminal 36.
Cleavage of both t-BOC and hemiaminal protecting groups and subsequent reaction of the
free amine with benzyl chloroformate and aqueous sodium carbonate in methylene
chloride provided 54% yield of N-benzyloxycarbonyl-amino alcohol 37. The choice of
protecting group on the amine terminus was important since it needed to withstand the
reaction conditions of the oxidation, and due to an earlier report that CBZ-protected amino
alcohols proceed with little or no racemization.34 Jones' oxidation of 37 afforded the
desired N-benzyloxycarbonyl-amino acid 38 in 70% yield.
The activation method of choice was conversion of 38 to the pentafluorophenyl
ester, since the reaction of N-benzyloxycarbonyl-S-benzyl-cysteine pentafluorophenyl
esters with glycine and other amino acids, has been shown to proceed quickly with
minimal racemization during peptide bond formation.35 (Less reactive active esters
reportedly result in considerably more racemization.) Reaction of the pentafluorophenyl
ester with glycine-t-butyl ester resulted in an overall coupling yield of 65% of the fully
protected dipeptide derivative 39. Selective N-debenzoylation of the cytosine protecting
group,36 and acylation with the ionizable protecting group resulted in 78% yield of the
dipeptide analogue 40. Both t-butyl ester and N-benzyloxycarbonyl protecting groups
were cleaved under acidic conditions, and the nitrogen terminus was tritylated37 to afford
47% yield of carboxylic acid 41. The carboxylic acid terminus was subsequently
activated as the p-nitrophenyl ester, to afford 61% of the desired activated monomeric
subunit 12. (D)-serine was similarly converted to the enantiomeric p-nitrophenyl ester
13, following the same sequence of synthetic transformations.30
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The stereochemical purity of compound 39 (following Jones' oxidation and peptide
bond formation) was similarly investigated, despite the previous report of Jones'
oxidation on N-CBZ-amino alcohols proceeding with little or no racemization.3420
Conversion of 39 to the Mosher's derived amides 43 and 44 is shown in Scheme IV.
High resolution NMR spectroscopic analysis of diastereomeric amides 43 and 44
revealed noticeable changes in the chemical shift of the methine proton at the stereocenter
of the subunit, and one of the methylene protons adjacent to the chiral center.
Consequently, it was confirmed that no racemization had occurred during either the
oxidation or coupling (within the limits of detection,1%), as evidenced by the absence
of any contaminating diastereomeric protons.
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C. Oligomer Synthesis
Activated monomer 10 was then utilized in solid-phase synthesis as described in
Scheme V. The apparatus utilized in the solid-phase syntheses is shown in Figure 5.
Cleavage of monomethoxytrityl on universal support 19, coupling of the resulting amine
with activated monomer 10, and capping of any unreacted amine with acetic anhydride
resulted in convenient stepwise elongation of subunits which, following five repetitions
and subsequent cleavage of fully protected hexamer from the solid support with DBU in
DMF, provided a highly efficient oligomerization (72% yield) of the protected hexamer
45 (and similarly hexamer 46, utilizing activated monomer 11). Compounds 45 and 46
were then subjected to mass spectral analysis. Positive FABMS of 45 (and 46) revealed
a single high molecular weight ion cluster at the expected 2827, corresponding to
[M+H]+.Structural confirmation of the corresponding free amines (following
detritylation and purification), was similarly obtained via positive FABMS.
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Figure 5. Apparatus for Solid-Phase Synthesis
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Hexamer 45 was then converted to a compound suitable for biophysical evaluation
as shown in Scheme VI. Reaction of 45 with dichloroacetic acid resulted in detritylation,
and the amine terminus was subsequently capped by treating with the mixed p-
nitrophenyl carbonate (derived from polyethylene glycol monomethyl ether, average MW
= 750 g/mol), 47.23Ion-exchange chromatographic purification on S-Sepharose,
ammonolysis, repurification, and subsequent desalting on polypropylene, provided the
desired compound 28. The same sequence of synthetic transformations gave rise to
hexamer 29 (derived from monomeric subunits of the opposite configuration), readily
obtainable from D-serine in an analogous fashion.
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Activated peptide subunit 12 was similarly taken on to solid-phase synthesis utilizing
universal support 19 (as described previously in Scheme V, for the synthesis of
hexamers 45 and 46). Due to a shortage of material however, the oligomerization in the
peptide series was attempted on a 5 mmol scale in which only a two-fold excess of the
activated subunit was employed. The coupling reactions were monitored utilizing UV
spectroscopy (by quantitating trityl at 432 nm). The combined C12HCCO2H washes and
CH2C12 rinses from each trityl deprotection reaction were evaporated in vacuo, and
dissolved in 20% F3CCO2H for UV assay. The initial attachment proceeded in 93%
yield, but after the second coupling only 23% remained attached to the solid-support.
Following the third coupling, a dismal 3% remained attached to the solid-support.
It was unclear at this point whether a poor coupling reaction was the source of our
problem, or whether we were simply working with unrealistically small amounts of
material (and solvent) in the coupling reactions. What had become evident, however,
was that more of the activated subunits 10 and 11 would be needed to enable the
synthesis of oligomers 16 and 17. During the time allotted to remake the activated
subunits, I opted to simultaneously investigate the proposed coupling reaction, through
the use of a model system which resembled the desired oligomers. Consequently,
attention was shifted to the valylglycine model oligomer 48, which was used to probe the
proposed coupling reaction and ascertain if a similarly hindered primary amine could be
efficiently coupled with an activated glycine residue.
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The synthesis of the activated subunit utilized in the model system is outlined in
Scheme VII. Valylglycine 49 was reacted with trityl bromide and triethylamine, which
following methanolysis afforded 42% yield of N-trityl-valylglycine 50. Activation of the
carboxylic acid as the p-nitrophenyl ester resulted in 55% yield of the activated model
subunit 51. The carboxyl terminus of the model was capped by reacting the activated
subunit directly with benzylamine, thereby affording intermediate 52 in 72% overall yield
from compound 50. The trityl protecting group was removed upon treatment with 4%
C12HCCO2H/CHC12. The amine salt was precipitated from 1:1 Et20:hexanes, and was
reacted with the activated model subunit 51 and triethylamine, to afford 74% yield of the
desired model oligomer 53.
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Having demonstrated that a similarly hindered primary amine could be reacted with
an activated glycine residue in solution, attention was shifted toward solid-phase27
assembly utilizing universal solid-support 19.The standard protocol previously
described in the synthesis of the urethane hexamers (Scheme V) was again followed, with
the exception that the model activated subunit 51 was employed. After three couplings
(quantitating each trityl deprotection reaction via UV at 432 nm), it was found that 93% of
the model oligomer remained attached to the solid-support. The results from the model
study, therefore, implied that it should be possible to adequately couple the modified
alanyiglycine subunits in the proposed manner.
It has recently been demonstrated that the amine terminus of the modified alanyl
subunit benzylamide 54, can also be effectively coupled with an activated glycine residue
as outlined in Scheme VIII. Consequently, this result further suggests that the proposed
methodology could be similarly applied to activated subunits 12 and 13, and enable the
solid-phase synthesis of the peptide-derived oligomers 16 and 17.
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D. Biophysical Testing
Each enantiomer of urethane-derived hexamer was analyzed for its ability to bind the
complementary DNA target p(dG)6 or RNA (poly G) utilizing thermal denaturation
experiments under low salt conditions.Neither 28 nor 29 was found to pair with
complementary RNA. Experimental results also indicated that 29 did not pair with its
target DNA. However, the (R)-configuration hexamer 28 was found to bind to its DNA
complement with Tm = 19°C, as evidenced by the characteristic melting curve shown in
Figure 6. The observed binding affinity of 28 with p(dG)6, albeit weaker than the
binding of the control oligomer, p(dC)6 (in which Tm = 32°C), demonstrates the
plausibility of hybridizing uncharged oligonucleotide analogues with native nucleic acids.
Figure 6. Thermal Denaturation of (R)-Urethane Hexamer 28 and p(dC)6 vs. p(dG)6
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Although both the (S)- and (R)-configurations of the 5-atom nylon-derived hexamers
(56 and 57, respectively) have been made previously,20,38 neither of these analogues has
to date been analyzed for its ability to bind with complementary DNA or RNA.
Consequently, we report here for the first time the results from the corresponding thermal
denaturation experiments, in which neither 56 nor 57 was found to pair with its
complementary DNA [p(dG)6)] or RNA [poly G] target under low salt conditions.
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III. CONCLUSIONS
Universal solid-support 19 has been developed to enable the solid-phase synthesis
of uncharged oligonucleotide analogues, and has been found to be a versatile means of
assembling a variety of amide- and carbamate-derived backbones. The synthesis of
mixed p-nitrophenyl carbonates 10 and 11 is also described herein, and these activated
subunits have been utilized in the solid-phase synthesis of the urethane-derived hexamers
45 and 46 (employing universal solid-support 19). The synthesis of p-nitrophenyl
esters 12 and 13 has also been described, and in due course, solid-phase methods will be
employed to assemble these (or related) activated subunits and complete the synthesis of
the peptide-derived oligomers 16 and 17.Both of the (R)-configuration activated
subunits 10 and 12 have been synthesized from a common synthetic intermediate 30,
and conversely, both of the (S)-configuration activated subunits 11 and 13 have been
synthesized from its enantiomer.31,32 Each class of the analogue subunits has also been
shown to be stereochemically pure, which is an important consideration if the completed
analogue oligomers are to possess a uniform binding constant for their complementary
nucleic acid targets.
The synthesis of the urethane-derived analogues was found to be convergent and
highly efficient, but in hindsight, there appear to be alternative (and more convergent)
routes toward the synthesis of the peptide-derived analogues. Hence, our original plan to
utilize a common synthetic intermediate for the synthesis of both the urethane- and
peptide-derived analogues might not have been the optimal method. The synthetic route
could perhaps be simplified considerably via an alkylation reaction, as envisioned in
Scheme IX, whereby cytosine could be attached to (and ring-open) the known lactone
58.39 Nevertheless, there appears to be one advantage for synthesizing the peptide-
derived subunits as described herein, and that is the ability to convert (L)-serine into the
unnatural (D)-configuration of the alanylglycine-derived peptide backbone.Scheme IX
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Another important consideration in the synthetic design of the peptide-derived
analogues, is the mode of subunit assembly during the solid-phase synthesis. The choice
to develop activated dipeptide subunits (such as 12 and 13) for the synthesis of the
desired hexamers, is preferable to the alternative approach (in which an activated alanyl-
derived monomer and an activated glycine residue would be employed), since only six
coupling reactions would be required during the solid-phase synthesis (as compared to
twelve in the alternative route). The proposed method for solid-phase synthesis of the
peptide-derived hexamers is advantageous, furthermore, since it utilizes an activated
glycine residue in all six of the dipeptide subunit coupling reactions. Six of the twelve
coupling reactions, in the alternative approach, would involve an activated modified
alanine residue (and the remaining six would involve an activated glycine residue).
Consequently, an in situ activation would be required for each alanyl-derived subunit
(prior to coupling with the free amine of the terminal glycine residue), since a more
reactive active ester than p-nitrophenyl would be required (e.g., pentafluorophenyl), in
order to prevent racemization during these particular coupling reactions.35
The proposed coupling reaction has been investigated in solution, and although it is
believed that an activated dipeptide subunit is the method of choice, we have recently
discovered that deprotected uncharged higher oligomers (22mers in another class of
analogues) are suitable for mass spectral analysis, if laser desorption mass spectrometry
(LDMS) is employed (unpublished results). In an effort to further simplify the synthesis
of the peptide-derived analogues, we therefore propose to utilize activated dipeptide32
subunits 60 and 61 (employing a t-butyl benzoyl protecting group on cytosine), since the
morpholine-derived protecting group has been found to no longer be necessary. Efforts
to synthesize the peptide-derived analogues 16 and 17 via solid-phase methods are
ongoing, and we hope to report on their biophysical (binding) properties in the near
future.
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Computer modeling studies had previously suggested that the S-configuration
urethane-derived hexamer 29, would be a more promising molecule than the R-
configuration hexamer 28 for binding to complementary DNA.19 Discrepancies between
the computer assisted predictions of duplex stability and the experimental binding results
imply perhaps, that simple searching and analysis of potential duplex conformations may
not be capable of determining whether uncharged oligonucleotide analogues are capable
of pairing with complementary nucleic acids. Nevertheless, the positive binding results
described herein for 28 (and the aforementioned successes reported in the literature24-29),
suggest that uncharged acyclic oligonucleotide analogues have potential merit as single-
stranded nucleic acid binding agents for diagnostic and therapeutic antisense applications.33
IV. EXPERIMENTAL
Methylene chloride (CH2C12),pyridine,dimethylformamide (DMF),
dimethylacetamide (DMA), and dimethyl sulfoxide (DMSO) were distilled from
powdered calcium hydride (CaH2) and stored over 3A/4A molecular sieves. Methanol
(MeOH) and ethanol (EtOH) were distilled from the corresponding magnesium
alkoxides and stored over 3A molecular sieves.Diethyl ether (Et20) was freshly
distilled from sodiumlbenzophenone prior to use. All other reagents were purified by
distillation or recrystallization prior to use whenever necessary. All moisture sensitive
reagents were transferred in a dry box or via a syringe under a positive pressure of
nitrogen. All moisture sensitive reactions were carried out under a positive pressure of
inert gas. Column chromatography was performed by using silica gel 60 (Merck, 340
400 mesh ASTM). Chromatography solvents were distilled before use.Analytical
TLC was conducted on precoated Merck silica gel 60 F254, J. T. Baker silica gel IB-F
or Merck aluminium oxide 60 F254 (neutral, type E) plates. The 1H-NMR spectra
(including 2D experiments) were taken on either AM-400 or AC-300 Bruker
spectrometers with tetramethylsilane (TMS) as internal standard. The chemical shifts
(8) are reported in parts per million (ppm) downfield from TMS. Infrared spectra (IR)
were obtained on a Nicolet 5DXB FT-IR spectrometer. Mass spectra were recorded on
a Kratos MS5ORF mass spectrometer. Ultraviolet spectra (UV) were obtained on an
IBM 9420 UV-Vis spectrophotometer. Optical rotations were measured with a Perkin-
Elmer model 243 polarimeter. Melting points were determined on a Buchi capillary
melting point apparatus and are not corrected. S-Sepharose was purchased from Sigma.
Thermal denaturation experiments, were performed utilizing a Carey 1 type UV-Vis
spectrophotometer (Varian).34
2-[ 2-( Monomethoxytrityl)aminoethoxy]- ethanol (21). To a 0°C solution of mono-
methoxytrityl chloride (3.09 g, 10.0 mmol) in anhydrous pyridine (20 mL), was added
2-(2-aminoethoxy)ethanol 20 (3.15 g, 30.0 mmol). The reaction mixture was allowed
to warm to RT over 30 min, and solvent was removed under reduced pressure. The
residue was dissolved in ethyl acetate (300 mL), washed with H2O (2 x 100 mL) and
satd NaHCO3 (2 x 100 mL), dried over anhydrous Na2SO4, filtered, and evaporated in
vacuo.The crude product was chromatographed twice (Si02, 3367% ethyl
acetate/hexane) to afford 2.83 g (75% yield) of 21 as an amber-colored glass. In order
to prevent decomposition, three drops of N,N-diethylaniline were added to the sample
prior to loading on the column. 1H NMR (300 MHz, DMSO-d6): 8 7.39 (2H, d, J =
7.53 Hz), 7.31 - 7.26 (6H, m), 7.17 (2H, t, J = 7.11), 6.86 (2H, d, J = 8.80 Hz), 4.56
(1H, t, J = 5.48 Hz, exchanged with D20), 3.72 (3H, s), 3.50 (2H, t, J = 6.10 Hz), 3.44
(2H, t, J = 5.20 Hz), 3.35 (2H, t, J = 5.05 Hz), 2.60 (1H, t, J =7.87 Hz), 2.13 (2H, q, J =
13.45,6.15 Hz).IR (Neat): 3423, 3326, 3058, 3027, 3001,2927, 2909, 2864, 1606,
1508,1450, 1298,1248, 1210, 1181, 1125, 1064, 1034, 905,831, 767, 706 cm-1. Pos.
FABMS, m/z (rel. intensity): 378.2 ([M+H]-1-, 3.2), 300.2 (24.4), 274.1 (37.8), 273.1
(100.0), 165.1 (7.8), 136.0 (6.7). HRMS (Pos. FABMS): calcd for C24H28NO3 [M+H]i-
378.2069, found 378.2068.
FM0C-proline-2'[2' -(monomethoxytrityl)aminoethoxy)-ethanoate(22).
Compound 21 (0.973 g, 2.58 mmol) was combined with FMOC-proline (1.22 g, 3.63
mmol) and 1-( 3- dimethylaminopropyl )- 3- ethylcarbodiimide methiodide (1.15 g, 3.87
mmol) in pyridine (12 mL) and allowed to stir at RT for 2 h. Additional carbodiimide
(0.340 g, 1.14 mmol) was then added and the reaction mixture was allowed to stir an
additional 2 h. A small portion of H2O (0.5 mL) was added, and the solvents were
removed under reduced pressure. The residue was dissolved in EtOAc (300 mL),35
washed with H2O (100 mL) and satd NaHCO3 (2 x 100 mL), dried over anhydrous
Na2SO4, filtered, and evaporated in vacuo. The crude product was chromatographed
(Si02, 33 67% ethyl acetate/hexane) to afford 1.34 g (74% yield) of 22 as a colorless
glass. In order to prevent decomposition, three drops of N,N-diethylaniline were added
to the sample prior to loading on the column. 1H NMR (300 MHz, DMSO-d6): 5 7.88
(2H, dd, J = 11.63, 7.57 Hz), 7.53 - 7.66 (2H, m), 7.447.21 (14H, m), 7.16 (2H, t, J =
7.12 Hz), 6.82 (2H, t, J = 8.21 Hz), 4.304.05 (6H, m), 3.70 (3H, s), 3.553.42 (4H,
m), 3.36 (2H, t, J = 6.89 Hz), 2.46 (1H, buried beneath DMSO), 2.202.05 (3H, m),
1.901.70 (3H, m). IR (KBr): 2951, 2880, 1746, 1705, 1606, 1508, 1449, 1417, 1349,
1296, 1275, 1248, 1179, 1121, 1087, 1033, 831, 763, 738, 705 cm-1. Pos. FABMS, m/z
(rel. intensity): 697.3 ([M+H] +, 4.0), 620.3 (3.9), 619.3 (9.1), 589.3 (2.2), 274.1 (31.1),
273.1 (100.0), 179.1 (18.9), 178.1 (11.1), 165.1 (7.8), 137.0 (8.9), 136.0 (14.4). Anal.
calcd for C44H44N206-0.5 H2O: C, 74.87; H, 6.43; N, 3.97. Found: C 74.83; H, 6.21;
N, 3.53. HRMS (Pos. FABMS): calcd for C44H45N206 [M+H]+ 697.3277, found
697.3281.
Anchor alcohol (24). Compound 22 (2.00 g, 2.90 mmol) was dissolved in DMF (40
mL) containing Et3N (10 mL), and heated at 50°C for 1 h. To this solution was added
2322 (1.50 g, 3.23 mmol) and the reaction mixture was evaporated under reduced
pressure at RT to a final volume of approximately 5 mL. This concentrated solution
was heated at 50°C for 2 h, at which time the solvent was removed in vacuo. The
residue was dissolved in EtOAc (200 mL) and washed successively with 0.15 M NaOH
(4 x 50 mL), H2O (100 mL), and satd NaC1 (100 mL). After drying over anhydrous
Na2SO4, the solution was filtered, and evaporated under reduced pressure. The crude
product was then chromatographed (Si02, 040% acetone/CHC13) to afford 1.80 g
(80% yield) of 24 as an amorphous white solid. 1H NMR (300 MHz, DMSO-d6): 636
7.89 (2H, t, J = 7.04 Hz), 7.74 (1H, t, J = 7.02), 7.707.62 (2H, m), 7.39 (4H, d, J =
7.68 Hz), 7.28 (6H, t, J = 7.08 Hz), 7.17 (2H, t, J = 7.20 Hz), 6.85 (2H, d, J = 8.70 Hz),
5.05 (1H, dd, J = 13.72, 4.00 Hz), 4.44 (1H, t, J = 7.21 Hz), 4.374.12 (5H, m), 4.10
3.95 (2H, m), 3.72 (3H, s), 3.65 - 3.45 (5H, m), 3.30 (2H, m), 3.02 (1H, dd, J = 10.63,
4.92 Hz), 2.83 (1H, br d), 2.54 (1H, buried beneath DMSO), 2.19 - 1.96 (4H, in), 1.92
1.68 (4H, m). IR (KBr): 3416, 2949,2916,2876,1743,1708, 1653, 1608, 1509, 1448,
1427, 1363, 1317, 1249, 1181, 1146,1086,1032,1006,831, 765, 730, 701 cm-1. Pos.
FABMS, m/z (rel. intensity): 801.5 (2.7), 800.5 ([M+H] +, 5.3), 722.3 (2.4), 528.4 (3.4),
526.4 (3.1), 307.1 (24.4), 289.1 (13.3), 274.1 (22.2), 273.1 (100.0), 165.1 (5.6), 138.0
(17.8), 137.0 (33.3), 136.0 (44.4). Anal. calcd for C43H49N3S010: C, 64.56; H, 6.17;
N, 5.25; S, 4.01. Found: C, 64.92; H, 5.95; N, 5.34; S, 3.94. HRMS (Pos. FABMS):
calcd for C43H50N3S010 [M+H]+ 800.3217, found 800.3220.
Activated anchor subunit (25). Protected dipeptide 24 (1.70 g, 2.10 mmol) and bis(p-
nitrophenyl) carbonate (1.40 g, 4.6 mmol) were dissolved in DMF (15 mL), and Et3N
(0.20 mL) was added. The reaction mixture was allowed to stir at RT for 1 h. To this
solution, H2O (1 mL in 2 mL of DMF) was added and the reaction was stirred an
additional 1 h at RT. Solvents were removed under reduced pressure, the residue was
dissolved in EtOAc (300 mL) and washed with 0.15 M NaOH (4 x 50 mL), H2O (2 x 50
mL), and satd NaCI (100 mL). The resulting solution was dried over anhydrous
Na2SO4, filtered, and evaporated under reduced pressure. The crude product was
chromatographed (SiO2, 0 20% acetone/CHC13) to afford 1.70 g (79% yield) of mixed
carbonate 25. 1H NMR (300 MHz, DMSO-d6): 8 8.33 (2H, dd, J = 9.12, 3.38 Hz), 7.91
(2H, dd, J = 6.95, 4.61, Hz), 7.807.55 (5H, m), 7.38 (4H, d, J = 7.73 Hz), 7.28 (6H, t,
J = 6.75 Hz), 7.17 (2H, t, J = 6.81 Hz), 6.85 (2H, d, J = 8.80 Hz), 5.21 (1H, br d), 4.57
(1H, t, J = 7.84 Hz), 4.40 - 4.25 (2H, m), 4.17 (1H, dd, J = 12.00, 5.36 Hz), 4.05 (1H,37
dd, J = 12.20, 4.85 Hz), 3.783.68 (5H, m, with 3H, s, at 3.71), 3.653.45 (6H, m),
3.30 (2H, m), 2.54 (1H, buried beneath DMSO), 2.202.00 (4H, m), 2.001.70 (4H,
m). IR (KBr): 3458, 2957, 2916, 2902, 2875, 1768, 1743, 1712, 1659, 1612, 1599,
1526, 1448, 1425, 1351, 1318, 1255, 1220, 1192, 1145, 1086, 1064, 1034, 858, 832,
766, 729, 702 cm-1. Pos. FABMS, m/z (rel. intensity): 966.3 (1.2), 965.3 ([M+H] +,
2.0), 887.3 (1.7), 693.2 (1.5), 691.2 (1.1), 307.1 (16.7), 289.1 (10.0), 274.1 (22.2), 273.1
(100.0), 165.1 (5.6), 138.0 (14.4), 137.0 (27.8), 136 (38.9). Anal. calcd for C43H49N3
SOio: C, 62.23; H, 5.43; N, 5.81; S, 3.32. Found: C, 61.83; H, 5.28; N, 5.56; S, 3.14.
HRMS (Pos. FABMS): calcd for C50H53N4S014 [M+H]+ 965.3279, found 965.3283.
Preparation of universal solid-support (19).1% crosslinked aminomethyl
polystyrene (60.0 mg, loading of 1.21 mmol/g) was treated according to the sequence of
steps described in Table 1. A 10 mL Biorad disposable polypropylene column and
vacuum filtration were utilized, following each rinse or reaction step (see Figure 5).
Table 1. Protocol for the Preparation of Universal Solid-Support 19
Steps Time Repetitions
1) DMF (1.0 mL) 15 min 1
2) 10% Diisopropylethylamine in DMF (0.5 mL) 10 min 1
3) DMF (1.0 mL) 1 min 5
4) Activated Anchor Subunit 25 30 min 1
(36.6 mg, 0.038 mmol) in DMF (1.0 mL)
5) DMF (1.0 mL) 1 min 5
6) p-Nitrophenyl methyl carbonate 1 h 1
(15.0 mg, 0.076 mmol) in DMF (1.0 mL)
7) DMF (1.0 mL) 1 min 5
The resin was then thoroughly dried under high vacuum to afford 80.0 mg of resin 19.38
Determination of monomethoxytrityl binding to resin 19 (loading). In a small vial,
34.5 mg resin 19 was swelled in 1 mL dimethylacetamide at RT for 15 h. The mixture
was transferred to a 10 mL Biorad disposable polypropylene column and filtered. The
resin was washed with CH2C12 (3 x 0.5 mL) and then stirred in 2%
CHC12CO2H/CH2C12 (0.5 mL) for 1 min. After filtration, 2% CHC12CO2H /CH2C12
(0.5 mL) was added and stirred for 7 min. The solid was washed with CH2C12 (3 x 0.5
mL). The acid filtrates and three washes were combined and evaporated in vacuo. The
monomethoxytrityl cation concentration was quantitated by UV at 476 nm in 20%
CF3CO2H/ CHC13 (e = 74,613). The loading capacity of dried resin 19 was found to be
2901.tmol/g.
Alkylation product (30).Hemiaminal alcohol 3131,32 (0.65 g, 2.81 mmol) was
dissolved in CH2C12 (3.50 mL) and cooled in an ice bath for 30 min, followed by
addition of N-methylimidazole (0.27 mL, 3.37 mmol). To this cold reaction mixture
was added dropwise a solution of tosyl chloride (0.59 g, 3.09 mmol) in CH2C12 (3.50
mL). The reaction mixture was stirred at 0°C for 30 min and allowed to stir for an
additional 20 h while slowly warming to RT. The reaction was quenched by addition of
H2O (1.0 mL) with vigorous stirring, diluted with CH2C12 (10 mL), washed with 2%
aq. NaHCO3 solution (3 x 3 mL), 0.5 M HC1 (3 x 3 mL), and satd NaCl (1 x 5 mL).
The solution was dried over anhydrous Na2SO4, filtered, and the solvent was removed
under reduced pressure to provide 1.03 g of a white solid. This crude product was
recrystallized from CHC13/hexanes to afford 0.76 g (71% yield) of pure tosylate as
white crystals, mp 114°C. [a]D22 = -42.6 (c = 0.50, CH2C12). 1H NMR (300 MHz,
CDC13): 8 7.80 (2H, d, J = 6.76 Hz), 7.35 (2H, d, J = 6.73 Hz), 4.163.78 (5H, m), 2.46
(3H, s), 1.561.46 (6H, 4 x s), 1.451.40 (9H, 2 x s). IR (KBr): 2956, 1698, 1369,
1177, 1093, 982, 827 cm-1. Pos. FABMS, m/z (rel. intensity): 386 ([M+H]+, 11.4), 33039
(47.1), 286 (38.6), 272 (100.0), 270 (32.9), 254 (10.7), 158 (14.3), 155 (13.6), 100
(20.7), 91 (14.0), 57 (70.0). Anal. calcd for C18F127NS06: C, 56.08; H, 7.06; N, 3.63;
S, 8.32. Found: C, 56.09; H, 7.11; N, 3.63; S, 8.25. HRMS (Pos. FABMS): calcd for
C18H28NS06 [M+H]+ 386.1637, found 386.1637.
Cytosine (2.31 g, 20.8 mmol) was mixed with potassium-tert-butoxide (2.32 g,
20.8 mmol) in DMSO (30 mL) and the resulting mixture was swirled with gentle
heating until a homogeneous solution formed. A solution of tosylate (4.00 g, 10.4
mmol) in DMSO (30 mL) was then added dropwise, and the reaction mixture was
gently warmed and allowed to stir at 65°C for 12 h. The reaction was quenched with
20% AcOH/CHC13 (80 mL). Following removal of solvents under reduced pressure,
the residual oil was taken up in 20% Me0H/CH2C12 (400 mL) and washed with 1M
NaOH (2 x 70 mL). The combined aqueous washes were back-extracted with CH2C12
(150 mL). The combined organic layers were then dried over anhydrous Na2SO4,
filtered, and solvent was removed in vacuo to afford 3.10 g of a white solid. This
material was subsequently purified by column chromatography (Si02, 1020%
Me0H/CHC13) to provide 2.56 g (76% yield) of white solid 30.Analytically pure
material was obtained from recrystallization in Me0H, to afford fine white crystals, mp
251-252°C (dec). [a]D22 = + 116.8 (c = 0.25, Me0H). 1H NMR (300 MHz, DMSO-
d6): 8 7.34 (1H, d, J = 7.1 Hz), 7.04 & 6.97 (2H, 2 br s, exchanged with D20), 5.62
(1H, d, J = 6.8 Hz), 4.25 - 4.05 (1H, m), 4.00 - 3.75 (3H, m), 3.653.40 (1H, m), 1.53
& 1.48 (6H, 2 x s), 1.39 & 1.32 (9H, 2 x s). IR (KBr): 3387, 3110, 3091, 1709, 1696,
1666, 1629, 1493, 1477, 1388, 1382, 1372, 1357, 1264, 1159, 1093 cm-1. Pos.
FABMS, m/z (rel. intensity): 326 (13.6), 325 ([M+H]+, 72.9), 269 (17.1), 225 (39.3),
211 (100.0), 193 (6.4), 167 (7.1), 136 (7.1), 125 (10.7), 112 (32.1), 57 (33.6). Anal.
calcd for C15H24N404: C, 55.54; H, 7.46; N, 17.27. Found C, 55.38; H, 7.61; N, 17.29.
HRMS (Pos. FABMS): calcd for C15H25N404 [M+H] +: 325.1875, found 325.1876.40
Mosher's ester (32). Alcohol 31 (52.5 mg, 0.227 mmol) was dissolved in anhydrous
CH2C12 (2.5 mL). (-)-a-Methoxy-a-(trifluoromethyl)phenylacetyl chloride33 (48.0
0.250 mmol) was added dropwise, followed by 4-dimethylaminopyridine (55.5 mg,
0.454 mmol), and the reaction mixture was allowed to stir at RT. After 2.5 h a few
drops of H2O were added with vigorous stirring. The reaction mixture was diluted with
CHC13 (25 mL) and extracted with 0.1 M HC1 (2 x 15 mL), satd NaHCO3 (2 x 15 mL),
and satd NaC1 (1 x 20 mL). The organic layer was dried over Na2SO4, filtered, and
evaporated in vacuo to afford 98.0 mg (96% yield) of colorless oil 32. 1H NMR (300
MHz, CDC13): 5 7.517.40 (5H, m), 4.63 - 4.51 (1H, m), 4.234.15 (1H, m), 4.05
3.96 (1H, m), 3.953.86 (1H, m), 3.79 (1H, dd, J = 9.17, 4.12 Hz), 3.53 (3H, s), 1.56
1.46 (15H, m with singlets).
Mosher's ester (33). By the same procedure as for 32, reaction of alcohol 31 (59.0 mg,
0.255 mmol) with (+)-a-Methoxy-a-(trifluoromethyephenylacetyl chloride33 (54.0 pL,
0.281 mmol) and 4-dimethylaminopyridine (62.3 mg, 0.510 mmol), resulted in 114 mg
(100% yield) of colorless oil 33. 1H NMR (300 MHz, CDC13): 8 7.517.40 (5H, m),
4.52 - 4.47 (1H, m), 4.24 - 4.16 (1H, m), 4.144.00 (1H, m), 3.90 (1H, dd, J = 9.29,
4.62 Hz), 3.75 (1H, dd, J = 9.06, 9.06 Hz), 3.54 (3H, s), 1.581.46 (15H, m with
singlets).Dramatic changes in chemical shift of two of the five oxazoline
ring/exocyclic methylene protons were observed [shifted from 4.634.51 (1H, m) and
4.05 - 3.96 (1H, m) in 32, to 4.524.47 (1H, m) and 4.14 4.00 (1H, m) in 33]. Within
the limits of detection (5_1%), neither diastereomer was found to be contaminated with
the other as evidenced by the absence of additional diastereomeric protons.41
Cytosine adduct with ionizable protecting group (34).Freshly prepared 4-(4-
morpholinyl)methylbenzoyl chloride22 (255 mg, 0.930 mmol) and cytosine hemiaminal
30 (200 mg, 0.620 mmol) was taken up in anhydrous pyridine (2 mL). The reaction
mixture was allowed to stir at RT for 18 h. The reaction mixture was cooled in an ice
bath and quenched by addition of H2O (0.5 mL). After 5 min at 0°C, conc. NH4OH
(0.5 mL) was added and the reaction mixture allowed to stir an additional 15 min at
0°C. Solvents were evaporated under reduced pressure and the resulting crude solid
was taken up in 1% Me0H/CHC13 (10 mL) and filtered to remove any remaining
undissolved solids prior to silica gel purification.Solvents were again removed in
vacuo and the resulting solid was purified by column chromatography (SiO2, 15%
Me0H/CHC13) to provide 280 mg (86% yield) of 34 as a white solid, mp 216°C (d).
[a]D22 = +92.0 (c = 0.05, Me0H). 1H NMR (300 MHz, DMSO-d6): 8 11.12 (1H, br d,
exchanged with D20), 7.97 (2H, d, J = 8.06 Hz), 7.91 (1H, m), 7.44 (2H, d, J = 8.14
Hz), 7.28 (1H, m), 4.31 (1H, m), 4.13 (1H, m), 3.92 (2H, m), 3.71 (1H, dd, J = 12.93,
8.07 Hz), 3.59 (4H, m), 3.53 (2H, s), 2.36 (4H, m), 1.41 - 1.28 (24 H, m with singlets).
JR (KBr): 3429, 2950, 1693, 1673, 1667, 1629, 1559, 1483, 1425, 1394, 1342, 1295,
1256, 1118, 1076cm-1. Pos. FABMS, m/z (rel. intensity): 528 ([M+H]+, 100.0), 428
(28.1), 204 (60.0), 147 (31.5), 136 (61.8), 118 (51.7), 105 (29.2), 90 (36.0). Anal. calcd
for C27H37N506: C, 61.46; H, 7.07; N, 13.27. Found: C, 61.39; H, 7.02; N, 13.19.
HRMS (Pos. FAB): calcd for C27H38N506 [M+H]+ 528.2822, found 528.2823.
N-Tr-Alcohol (35). BOC-hemiaminal 34 (50.0 mg, 0.095 mmol) was taken up in
CH2C12 (0.7 mL). To this solution was added CF3CO2H (0.70 mL) at RT with stirring.
After 1 h, the reaction mixture was evaporated under reduced pressure. The resulting
oily residue was dissolved in 80% aq. AcOH (2 mL), allowed to stir at RT for 12 h, and
Ts0H-H20 (36.1 mg, 0.190 mmol) was added prior to evaporating the reaction mixture42
in vacuo. Residual H2O and AcOH was removed by three consecutive coevaporations
with anhydrous DMF, and the sample was placed under high vacuum for 12 h prior to
reprotection of the amine. The crude amine salt was dissolved in 0.5 mL anhydrous
DMF, trityl chloride (79.0 mg, 0.280 mmol) was added, followed by the addition of
Et3N (0.13 mL, 0.950 mmol). After stirring at RT for 1 h, the reaction mixture was
diluted with CHC13 (15 mL) and extracted with satd NaHCO3 (3 x 6 mL) and satd NaC1
(1 x 6 mL). The organic layer was dried over Na2SO4, filtered, and evaporated in
vacuo. Purification of the residual oil (SiO2, 12.5% Me0H/CHC13) resulted in 36.1
mg (60% yield) of white solid 35, mp 149-151°C.[a]D22 = -20.0 (c = 0.05, CH2C12).
1H NMR (400 MHz, DMSO-d6): 8 11.24 (1H, s, exchanged with D20), 8.18 (2H, d, J =
7.2 Hz), 8.00 (2H, d, J = 8.2 Hz), 7.45 (2H, d, J = 8.3 Hz), 7.38 (6H, d, J = 7.3 Hz), 7.27
7.14 (10 H, m), 4.43 (1H, t, J = 5.05 Hz, exchanged with D20), 3.93 (1H, m), 3.75
(1H, m), 3.58 (4H, m), 3.54 (2H, s), 2.92 (2H, br m, 1H exchanged with D20), 2.60
2.50 (1H, m, confirmed by COSY and high temperature NMR to be buried beneath
DMSO solvent peak), 2.37 (4H, m), 2.202.10 (1H, m). TR (KBr): 3406, 2955, 2929,
2856, 1697, 1653, 1624, 1485, 1449, 1365, 1350, 1246, 1116 cm-1. Pos. FABMS, rniz
(rel. intensity): 669 ([MH+K] f, 3.9), 630 ([M-4-1] ±, 6.4), 628 (5.2), 552 (3.3), 386 (6.7),
315 (5.3), 307 (4.0), 259 (6.1), 244 (68.9), 243 (100.0), 165 (66.7).Anal. calcd for
C38H39N504.0.5 H2O: C, 71.45; H, 6.31; N, 10.97. Found: C, 71.53; H, 6.18; N, 10.64.
HRMS (Pos. FAB): calcd for C38H40N504 [M+H]+ 630.3080, found 630.3078.
Activated monomer (10).N-Trityl-alcohol 35 (57.2 mg, 0.091 mmol) and bis(p-
nitrophenyl) carbonate (50.0 mg, 0.163 mmol) was taken up in anhydrous CH2C12 (0.15
mL). Et3N (50 mL, 0.362 mmol) was added and the reaction mixture allowed to stir at
RT for 2 h. The reaction mixture was then diluted with CHC13 (20 mL) and extracted
with 0.01 M NaOH (4 x 5 mL), H2O (2 x 5 mL), and satd NaC1 (1 x 5 mL). The43
organic layer was dried over MgSO4, filtered, and evaporated under reduced pressure.
Purification on silica (12.5% Me0H/CHC13) resulted in 72.3 mg (100% yield) of
white solid 10, mp 133-134°C. [a]D22 (c = 0.95, CH2C12). 1H NMR (300
MHz, DMSO-d6): 8 11.25 (1H, s), 8.28 (2H, d, J = 7.91 Hz), 7.38 (6H, d, J = 7.71 Hz),
7.297.16 (10 H, m with d, J = 7.58 Hz), 4.08 (1H, m), 3.67 (1H, m), 3.58 (4H, m),
3.54 (2H, s), 3.21 (2H, br m), 2.602.50 (1H, m, buried beneath DMSO), 2.37 (4H, m),
1.75 (1H, m). IR (1(13r): 3390 br, 1772, 1697, 1686, 1664, 1658, 1623, 1594, 1557,
1525, 1487, 1448, 1370,1348, 1316, 1301, 1249,1213,1114 cm-1 Pos. FABMS, m/z
(rel. intensity): 796 (2.1),795 ([M+H] +, 4.3), 551(2.4),328 (2.3), 315 (2.1), 307 (2.1),
289 (2.2), 267 (2.4), 244(28.9), 243 (100.0), 165(37.8), 136 (26.7). Anal. calcd for
C45H42N608-H20: C, 66.49; H, 5.46; N, 10.34. Found: C, 66.39; H, 5.28; N, 9.97.
HRMS (Pos. FAB): calcd for C45H43N608 [M+FI]+ 795.3142, found 795.3143.
Activated monomer (11).Spectroscopic properties of D-serine derived activated
monomer 11 were identical to those for L-serine derived intermediate 10, with the
exception of optical rotation which was of equal and opposite magnitude. [a]D22
-25.76 (c = 0.66, CH2C12).
N-CBZ-Alcohol (37). Compound 36 (0.78 g, 1.61 mmol) was dissolved in CH2C12
(10 mL) and trifluoroacetic acid (10 mL) was added at RT with stirring. The reaction
mixture was allowed to stir for 1 h and following removal of solvent, the residue was
dissolved in 80% aq. AcOH (20 mL) and allowed to stir at RT for 12 h. The reaction
mixture was then evaporated under reduced pressure and the residual oil was
coevaporated twice with hexane (50 mL portions). The residue was then thoroughly
dried under high vacuum for 12 h, anhydrous CH2C12 (10 mL) and 1 M aq. Na2CO3
(6.44 mL, 6.44 mmol) were added, followed by dropwise addition of benzyl44
chloroformate (0.32 mL, 2.25 mmol) at RT with vigorous stirring. The reaction mixture
was allowed to continue stirring vigorously for 12 h. The reaction mixture was diluted
with CH2C12 (50 mL) and extracted with 5% aq. NaHCO3 (3 x 20 mL), 0.5 M HC1 (1 x
20 mL), and satd NaC1 (1 x 20 mL). Following drying over Na2SO4 and removal of
solvent, the colorless syrup was purified by column chromatography (SiO2, 12.5%
Me0H/CHC13) to afford 0.50 g (54% yield) of an amorphous white solid 37, mp 121°C.
[a]D22 = +129.0 (c = 0.10, Me0H). 1H NMR (300 MHz, DMSO-d6): S 11.08 (1H, s),
7.997.95 (3H, m with 2H, d, J = 8.39 Hz), 7.54 (2H, d, J = 8.49 Hz), 7.34 (6H, m),
5.024.88 (3H, m with 2H, AN, JAB = 12.77 Hz, AVAB = 25.57 Hz), 4.21 (1H, dd, J =
13.1, 3.60 Hz), 3.94 (1H, m), 3.583.38 (3H, m), 1.31 (9H, s). IR (KBr): 3367, 3334,
2965, 1686, 1658, 1653, 1627, 1560, 1538, 1523, 1502, 1497, 1488, 1373, 1250, 1093
cm-1. Pos. FABMS, m/z (rel. intensity): 480 (34.0), 479 ([M+H]+, 89.8), 272 (5.4),
161 (100.0), 146 (5.7), 118 (4.8), 91 (30.6). Anal. calcd for C26H30N405: C, 65.26; H,
6.32; N, 11.71. Found: C, 65.24; H, 6.21; N, 11.94. HRMS (Pos. FAB): calcd for
C26H31N405 [M+1-1]+ 479.2294, found 4742299.
N-CBZ-Carboxylic acid (38). Compound 37 (159 mg, 0.33 mmol) was dissolved in
acetone (2 mL) and added dropwise to a solution of Jones' reagent36 (1.5 mL) in
acetone (1 mL) at 0°C.Additional acetone (1 mL) was added to the flask which
previously contained compound 37, swirled, and added to the reaction vessel. The
reaction mixture was allowed to stir at 0°C for 8 h, at which time isopropanol (4 mL)
was added. After 30 min at 0°C, the reaction mixture was diluted with acetone (20 mL)
and, following thorough mixing, the organic layer was decanted. This procedure was
repeated three times and the organic washes were combined and evaporated in vacuo.
The residue was taken up in H2O and extracted with EtOAc (3 x 40 mL), dried over
Na2SO4, and evaporated under reduced pressure. The resulting white solid was dried45
further under high vacuum and then purified chromatographically (Si02, 1.2520%
Me0H/CHC13) to afford 115 mg (70% yield) of a white solid 38, mp 219-220°C(d).
[a]D22 = +116.0 (c = 0.05, Me0H). 1H NMR (300 MHz, DMSO-d6): 8 11.04 (1H, s),
7.97 (2H, d, J = 8.04 Hz), 7.53 (2H, d, J = 8.27 Hz), 7.367.16 (6H, m), 6.82 (1H, br
d), 4.93 (2H, ABq, JAB = 12.68 Hz, AvAB = 29.42 Hz), 4.54 (1H, m), 4.18 (1H, m),
3.56 (1H, t, J = 12.02 Hz), 1.31 (9H, s). IR (KBr): 36003100 br, 2903, 1701, 1691,
1651, 1644, 1642, 1640, 1638, 1627, 1623, 1611, 1608, 1571, 1564, 1561, 1487, 1428,
1425, 1363, 1325, 1297, 1254 cm-1. Pos. FABMS, m/z (rel. intensity): 494 (20.4), 493
([M+H]-1-, 61.3), 310 (38.8), 272 (20.4), 216 (39.5), 161 (100.0), 91 (57.9). Anal. calcd
for C26H28N406-0.5 H2O: C, 62.26; H, 5.83; N, 11.17. Found: C, 62.25; H, 5.65; N,
11.14. HRMS (Pos. FAB): calcd for C26H29N406 [M+H]-1- 493.2087, found 493.2088.
N-CBZ-Dipeptide (39). Carboxylic acid 38 (0.56 g, 1.14 mmol), pentafluorophenol
(2.09 g, 11.4 mmol), and 1-( 3- dimethylaminopropyl )- 3- ethylcarbodiimide methiodide
(0.68 g, 2.27 mmol) were dissolved in CH2C12 (20 mL) and cooled to 0°C. 4-Dimethyl-
aminopyridine (61 mg, 0.57 mmol) was added and the reaction mixture was allowed to
stir 8 h under inert atmosphere while slowly warming to RT. Glycine-t-butyl ester
hydrochloride (0.21 g, 1.25 mmol) was then added, followed by the addition of Et3N
(1.58 mL, 11.4 mmol). After 4 h, the reaction mixture was diluted with CHC13 (300
mL) and extracted with H2O (1 x 75mL), 0.15 M NaOH (3 x 75 mL), and satd NaC1 (1
x 100 mL). Each aqueous extract was then back-extracted with CHC13 (200 mL). The
combined organic extracts were then dried over Na2SO4, filterered, and evaporated in
vacuo. The crude product was purified via column chromatography (Si02, 1.252.5%
Me0H/CHC13) to provide 0.44 g (64% yield) of white solid 39, mp 119-120°C.[00D22
= +59.52 (c = 0.50, CH2C12). 1H NMR (300 MHz, DMSO-d6): 8 11.12 (1H, s), 8.48
(1H, t, J = 5.46 Hz), 8.057.92 (3H, m with 2H, d, J = 8.29 Hz at 7.98), 7.69 (1H, d, J46
= 9.32 Hz), 7.54 (2H, d, J = 8.35 Hz), 7.407.18 (6H, m), 4.98 (2H, ABq, JAB = 12.70
Hz, AVAB = 32.50 Hz), 4.674.51 (1H, m), 4.40 (1H, dd, J = 13.51, 3.43 Hz), 3.85 -
3.60 (3H, m), 1.41 (9H, s), 1.31 (9H, s). IR (KBr): 3284 br, 2966. 1724, 1689, 1674,
1666, 1629, 1554, 1484, 1425, 1365, 1301, 1252,1157,1113, 1051, 791,747, 698 cm-
1. Pos. FABMS, m/z (rel. intensity): 607.3 (18.2),606.3([M+H]+, 48.2),550.3 (24.7),
272.1 (10.6), 162.1 (12.9), 161.1 (100.0), 91.1 (30.6), 57.1 (9.4).Anal. calcd for
C32H39N507: C, 63.46; H, 6.49; N, 11.56. Found: C, 63.34; H, 6.75; N, 11.34. HRMS
(Pos. FAB): calcd for C32H40N507 [M+H]+ 606.2927, found 606.2927.
N-CBZ-Dipeptide with ionizable base protecting group (40). Dipeptide 39 (52 mg,
0.086 mmol) was dissolved in 8:2 pyridine:HOAc (0.18 mL). Hydrazine monohydrate
(17 p.L, 0.34 mmol) was then added, and the reaction mixture was allowed to stir at RT
for 22 h. Solvents were removed under reduced pressure and the resulting residue was
purified chromatographically (SiO2, 2.510% Me0H/ CHC13) to afford 35 mg (91%
yield) of the free cytosine adduct as a beige solid, mp 170-171°C.[a]D22 = 88.38 (c
0.50, Me0H). 1H NMR (300 MHz, DMSO-d6): 8 8.36 (1H, t, J = 5.61 Hz), 7.59 (1H,
d, J = 8.79 Hz), 7.44 (1H, d, J = 7.23 Hz), 7.40 - 7.24 (5H, m), 7.156.95 (2H, br d),
5.60 (1H, d, J = 7.05 Hz), 5.00 (2H, ABq, JAB = 12.84 Hz, AVAB = 22.86 Hz), 4.50
4.38 (1H, m), 4.284.12 (1H, dd, J = 13.37, 9.89 Hz), L41 (9H, s). IR (KBr): 3415 br,
3330 br, 1739, 1673, 1652, 1528, 1498,1377,1280,1251, 1228, 1158 cm-1. Pos.
FABMS, m/z (rel. intensity): 892.3 (17.1),891.3(35.0),447.1 (25.7), 446.1 ([M+H]±,
48.6), 391.1 (20.7), 390.1 (100.0).Anal. calcd for C21H27N506-H20: C, 54.42; H,
6.31; N, 15.11. Found: C, 54.50; H, 6.38; N, 14.78. HRMS (Pos. FAB): calcd for
C21H281\1506 [M+H]+ 446.2039, found 446.2038.
Anhydrous pyridine (0.2 mL) was added to a flask containing the free cytosine
adduct (35 mg, 0.079 mmol) and freshly prepared 4-(4-morpholinyl)methylbenzoyl47
chloride (108 mg, 0.393 mmol). The reaction mixture was allowed to stir at RT under
an inert atmosphere for 3 h. The reaction mixture was then externally cooled to 0°C.
H2O (0.30 mL) was added and after 5 min, conc. NH3 (0.30 mL) was added and
allowed to stir for an additional 15 min at 0°C. Solvents were removed in vacuo, and
the crude product was purified by chromatography (Si02, 1.255.0% Me0H/CHC13)
to afford 30 mg (59% yield) of white solid 40, mp 170-171°C. [a]D22 = +55.31 (c =
0.50, CH2C12). 1H NMR (300 MHz, DMSO-d6): 8 11.15 (1H, s), 8.48 (1H, t, J = 5.96
Hz), 8.06 - 7.90 (3H, m with 2H, d, J = 8.07 Hz at 7.99), 7.67 (1H, d, J = 9.93 Hz), 7.45
(2H, d, J = 8.27 Hz), 7.407.18 (6H, m), 4.98 (2H, ABq, JAB = 12.77 Hz, AVAB=
31.29 Hz), 4.65 - 4.50 (1H, m), 4.48 - 4.32 (1H, m), 3.853.64 (3H, m), 3.58 (4H, m),
3.54 (2H, s), 2.37 (4H, m), 1.41 (9H, s). IR (KBr): 3325 br, 1728, 1691, 1659, 1622,
1546, 1542, 1497, 1455, 1420, 1364, 1301, 1259, 1247, 1156, 1116, 1048, 797, 747,
697 cm-1. Pos. FABMS, m/z (rel. intensity): 650.1 (33.3), 649.1 ([M+H]+, 100.0),
593.0 (26.7), 488.1 (31.1), 432.0 (28.9), 204.1 (34.4), 91.1 (86.7).Anal. calcd for
C33H40N608: C, 61.10; H, 6.22; N, 12.95. Found: C, 60.80; H, 6.12; N, 13.06. HRMS
(Pos. FAB): calcd for C33H41N608 [M+H]+ 649.2986, found 649.2985.
N-Tr-Dipeptide carboxylic acid with ionizable protecting group (41).Compound
40 (300 mg, 0.462 mmol) was dissolved in CH2C12 (2.0 mL) at RT. This solution was
allowed to stir while F3CCO2H (2.0 mL) was slowly added. After 1 h, the reaction
mixture was evaporated in vacuo and the residue was purified via column
chromatography (Si02, 10:2:88 MeOH:HOAc:CHC1320:2:78 MeOH:HOAc:CHC13)
to afford 314 mg (96% yield) of pure carboxylic acid, mp 153°C (d). 1H NMR (300
MHz, DMSO-d6): 8 12.30 (1H, br s, exchanges with D20), 11.21 (1H, br s, exchanges
with D20), 8.43 (1H, t, J = 5.42 Hz), 8.08 (2H, d, J = 7.09 Hz), 7.96 (1H, d, J = 7.33
Hz), 7.67 (1H, d, J = 9.20 Hz), 7.647.48 (2H, br d), 7.407.18 (6H, m), 4.98 (2H,48
ABq, JAB = 12.70 Hz, AVAB = 34.08 Hz), 4.58 (1H, m), 4.41 (1H, dd, 13.19, 3.83 Hz),
3.953.53 (9H, m), 2.542.47 (4H, m, buried beneath DMSO). IR (KBr): 3391 br,
1674 br, 1666, 1631, 1565, 1516, 1488, 1457, 1421, 1364, 1307, 1256, 1197, 1127,
1084, 1057, 753 cm-1. Pos. FABMS, rri/z (rel. intensity): 615.3 ([M+Na] -F, 40.0), 593.3
([M+11]±, 65.0), 329.1 (40.0), 221.3 (60.0), 219.1 (45.0), 205.1 (45.0), 176.1 (100.0).
HRMS (Pos. FAB): calcd for C271133N608 [M+E-1]-1- 593.2360, found 593.2361.
The carboxylic acid (311 mg, 0.440 mmol) was taken up in HBrHOAc (4.0 mL).
The reaction mixture was allowed to stir at RT for 25 min. Anhydrous Et20 (10 mL)
was added with vigorous stirring and the resulting precipitate was collected by
centrifugation. The pellet was triturated three times with additional anhydrous Et20 (20
mL portions) and the solid was dried under reduced pressure. The dried solid was
dissolved in 2:1 DMF:CHC13 (5.0 mL) and trityl bromide (711 mg, 2.20 mmol) was
added in one portion.37 The reaction mixture was allowed to stir 1 h at RT, Et3N (0.61
mL, 4.40 mmol) was added and the reaction mixture was allowed to stir an additional 1
h at RT. Me0H (6.0 mL) was then added and the reaction mixture was stirred for 3 h at
60°C. Solvents were removed in vacuo and the residue was triturated with anhydrous
Et20 (6 x 15 mL portions). To the solid was added CH2C12 (30 mL) and pH 6
phosphate buffer (30 mL). The aqueous layer at pH 6 (the isoelectric point) was further
extracted with CH2C12 (2 x 30 mL), and the combined organic layers were extracted
with satd NaCl (20 mL). After drying over Na2SO4 and removal of solvent under
reduced pressure, the crude orange solid (213 mg) was purified by column
chromatography (Si02, 1.2520.0% MeOH:CHC13) to afford 150 mg (49% yield) of
white solid 41, mp 190-191°C(d). [a]D22 = 46.09 (c = 0.50, CH2C12). 1H NMR (300
MHz, DMSO-d6): 8 11.26 (1H, br s), 8.32 (1H, d, J = 7.25 Hz), 8.01 (2H, d, J = 8.23
Hz), 7.45 (2H, d, J = 8.32 Hz), 7.37 (1H, d, J = 6.84 Hz), 7.357.08 (17H, m), 3.95
(1H, dd, J = 13.19, 3.29 Hz), 3.73 (1H, dd, J = 13.20, 8.81 Hz), 3.58 (4H, m), 3.54 (2H,
s), 3.10 (1H, dd, J = 17.34, 4.81), 2.88 (1H, dd, J = 16.86, 3.57), 2.36 (4H, m). IR49
(KBr): 3402 br, 1697, 1667, 1654, 1621, 1587, 1562, 1486, 1450, 1446, 1420, 1403,
1369, 1309, 1245, 1114, 790, 750, 704 cm-1. Pos. FABMS, m/z (rel. intensity): 739.3
([M+K]+, 1.1), 723.3 ([M+Na]+, 1.6),701.3([M+F1]-1-, 1.6),460.13.1), 459.1 (1.4),
457.1 (1.7), 413.2 (1.4), 244.1 (25.0),243.1(100.0), 165.1(21.4).Anal. calcd for
C401-140N606H20: C, 66.84; H, 5.89; N, 11.69. Found: C, 66.86; H, 5.28; N, 11.73.
HRMS (Pos. FAB): calcd for C401-141N606 [M+H]+ 701.3087, found 701.3085.
N-Tr-Dipeptide activated subunit (12). Anhydrous pyridine (0.10 mL) was added to
a mixture of compound 41 (10 mg, 0.0145 mmol) and bis(p-nitrophenyl)carbonate (22
mg, 0.0725 mmol).After 20 h at RT, the reaction mixture was diluted with 20%
isopropanol/CHC13 (20 mL) and extracted with 0.15 M NaOH (4 x 5 mL), pH 7 buffer
(2 x 5 mL), and satd NaC1 (1 x 10 mL). The organic layer was dried over MgSO4, and
solvent was removed in vacuo. The product was purified on SiO2 (1.252.5%
Me0H/CHC13) to afford 7.3 mg (61% yield) of a white solid 12, mp 128-129°C (d).
[a]D22 = 32.06 (c = 0.10, CH2C12). Compound 12 could also be made from 41 and p-
nitrophenol via carbodiimide coupling, although the use of 4-dimethylaminopyridine
was found to lead to complications during the workup and isolation, and should
therefore be avoided. 1H NMR 400 MHz, DMSO-d6): 5 11.20 (1H, br s, exchanges
with D20), 8.338.21 (3H, m with 2H, d, J = 8.93 Hz at 8.26), 7.99 (2H, d, J = 8.03
Hz), 7.44 (2H, d, J = 8.08 Hz), 7.407.10 (20H, m), 4.023.92 (1H, m), 3.803.60
(2H, m), 3.58 (4H, m), 3.54 (2H, s), 3.42 - 3.32 (2H, m), 2.37 (4H, m). IR (KBr): 3427
br, 1673, 1666, 1660, 1639, 1628, 1560, 1522, 1486, 1456, 1450, 1367, 1359, 1351,
1347, 1302, 1247, 1206, 1136, 1114, 790, 750, 706 cm-1.Pos. FABMS, miz (rel.
intensity): 823.3 (1.5), 822.3 ([M+H]+, 2.7), 821.3 (0.8), 820.3 (1.0), 578.2 (1.1), 244.2
(20.9), 243.2 (100.0), 165.2 (16.3). HRMS (Pos. FAB): calcd for C46H44N708
[M+H]+ 822.3251, found 822.3252.50
N-CBZ-Dipeptide benzylamide (42). Compound 38 (56 mg, 0.102 mmol) and p-
nitrophenol (142 mg, 1.02 mmol) were dissolved in DMF (1 mL) and cooled to 0°C.
The 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide methiodide (76 mg, 0.255 mmol)
and 4-dimethylaminopyridine (2 mg, 0.020 mmol) were added and the reaction mixture
was allowed to stir for 8 h while gradually warming to RT. Benzylamine (56 pL, 0.510
mmol) and Et3N (142 !IL, 1.02 mmol) were added and the reaction mixture was allowed
to stir an additional 8 h. The reaction mixture was diluted with 20% isopropanol/CHC13
(40 mL) and extracted with 0.15 M NaOH (4 x 10 mL), 0.5 M HC1 (1 x 10 mL), and
satd NaC1 (1 x 10 mL). The resulting product was purified on SiO2 (1.25 - 2.5%
Me0H/CHC13) to afford 37 mg (57% yield) of 42 as a white solid. 1H NMR (400
MHz, DMSO-d6): 8 11.08 (1H, s), 8.41 (1H, t, J = 5.87 Hz), 8.28 (1H, t, J = 5.67 Hz),
7.98 (2H, d, J = 8.31 Hz), 7.94 (1H, d, J = 7.48 Hz), 7.70 (1H, d, J = 8.37 Hz), 7.54 (2H,
d, J = 8.47 Hz), 7.404.18 (11H, m), 4.95 (2H, ABq, JAB = 12.68 Hz, AVAB = 37.08
Hz), 4.54 (1H, m), 4.454.35 (1H, m), 4.30 (2H, d, J = 5.92 Hz), 4.864.70 (3H, m
with 2H, d, J = 5.81 Hz at 3.76), 1.31 (9H, s). Pos. FABMS, m/z (rel. intensity): 640.2
(10.0), 639.2 ([M+H]+, 24.2), 272.1 (12.2), 161.1 (100.0), 91.1 (66.7), 77.1 (35.6).
HRMS (Pos. FAB): calcd for C35H39N606 [M+H]+ 639.2931, found 639.2933.
Mosher's amide (43).Compound 42 (6.4 mg, 0.010 mmol) was dissolved in
HBrHOAc (0.5 mL) and was allowed to stir for 15 min at RT. Anhydrous Et20 (5 mL)
was added to precipitate the amine salt, which was subsequently triturated with Et20 (4
x 5 mL). The amine salt was dried for 2 h in vacuo, and was dissolved in anhydrous
pyridine (0.10 mL) (-)-a-Methoxy-a-(trifluoromethyl)phenylacetyl chloride33 (2.1 pL,
0.011 mmol) and Et3N (14 p.L, 0.10 mmol) were added and the reaction mixture was
allowed to stir for 2 h at RT. A few drops of H2O were added and the reaction was
stirred vigorously for 5 min. The reaction mixture was diluted with CHC13 (20 mL) and51
extracted with 0.10 M NaOH (2 x 5 mL), satd NaHCO3 (2 x 5 mL), and satd NaC1 (1 x
5 mL). The organic layer was dried over Na2SO4 and the solvent was removed in
vacuo to afford 6.0 mg (83% yield) of 43 as a white solid, which was examined by
NMR without further purification. 1H NMR (300 MHz, DMSO-d6): 5 11.12 (1H, s),
8.67 (1H, d, J = 7.92 Hz), 8.44 (1H, t, J = 6.11 Hz), 8.33 (1H, t, J = 5.57 Hz), 8.06
7.92 (3H, m with 2H, d, J = 8.51 Hz at 8.00), 7.80 (1H, d, J = 7.19 Hz), 7.62 - 7.48 (3H,
m with 2H, d, J = 8.27 Hz at 7.56), 7.427.18 (8H, m), 7.05 (1H, d, J = 6.80 Hz), 5.02
4.92 (1H, m), 4.40 - 3.94 (1H, m), 3.923.72 (2H, m), 3.48 (3H, s), 1.32 (9H, s).
Mosher's amide (44). By the same procedure as for 43, reaction of the free amine of
42 with (+)-a-Methoxy-a-(trifluoromethyl)phenylacetyl chloride33 (2.1 1.1L, 0.011
mmol) and Et3N (14 pL, 0.10 mmol) in pyridine (0.10 mL), resulted in 5.8 mg (81%
yield) of 44 as a white solid. 1H NMR (300 MHz, DMSO-d6): 5 11.12 (1H, s), 8.87
(1H, d, J = 7.03 Hz), 8.41 (1H, t, J = 5.94 Hz), 8.29 (1H, t, J = 5.62 Hz), 8.04 (1H, d, J =
7.47 Hz), 7.97 (2H, d, J = 8.46 Hz), 7.62 - 7.48 (3H, m with 2H, d, J = 8.40 Hz at 7.53),
7.487.38 (2H, m), 7.387.18(8H, m), 4.924.82(1H, m), 4.424.34 (1H, m), 4.30
(2H, d, J = 5.96 Hz), 4.184.06(1H, m), 3.883.73(2H, m), 3.47(3H, s), 1.31 (9H, s).
Dramatic changes in the chemical shift of the methine proton at the stereocenter of the
subunit, and one of the methylene protons adjacent to the chiral center were observed
[shifted from 5.024.92 (1H, m) and 4.063.94 (1H, m) in 43, to 4.924.82 (1H, m)
and 4.18 - 4.06 (1H, m) in 44].Within the limits of detection (1%), neither
diastereomer was found to be contaminated with the other as evidenced by the absence
of additional diastereomeric protons.52
Solid-phase synthesis of oligomers (45 and 46). Resin 19 (34.5 mg, 10.0 wnol) was
swelled with DMA (1 mL) in a small vial at RT for 16 h. The apparatus utilized in the
solid-phase syntheses is shown in Figure 5. The mixture was transferred to a 10 mL
Biorad disposable column, DMA was removed via filtration, and the sequence of steps
in Table 2 was performed at RT with the exception of step 8 (which was run at 40°C).
Each step was performed with external agitation utilizing a spatula which had been
penetrated through a septum, stoppered at the top of the column.Mixing of the
suspension was facilitated by an external motor with a cam, used to gently rock the
spatula back and forth.(Vigorous stirring was found to degrade the solid support.)
Reagents were introduced via syringe, through the serum stopper.Following
oligomerization the resin was rinsed with DMF (3 x 0.5 mL, at 3 min intervals), and the
desired hexamer was cleaved from the solid support by treating with a solution of DBU
(601.1L), diethyl malonate (30114 and DMF (1.0 mL) at RT for 1 h with agitation. The
supernatant solution was removed by filtration and the resin was again rinsed with DMF
(3 x 0.5 mL). The combined filtrates were evaporated in vacuo without external
heating, the resulting residual oil was dissolved in a minimum amount of CH2C12, and
precipitated by addition of 1:1 anhydrous Et20/hexanes (4 mL).Following
centrifugation, the solvent was decanted and the precipitation repeated. The crude
hexamer was dried under high vacuum to afford 20.4 mg (72%, or approximately 95%
per step based on overall yield) of beige solid 45. Pos. FABMS of 45 (and 46) revealed
a single high molecular weight ion cluster centered at the expected 2827, corresponding
to [M+H]+. Upon ion-exchange analysis on S-Sepharose the product appeared in the
chromatographic profile to be one major peak, using 0.02 M phosphate buffer (pH 2.5)
and a gradient of KC1 (01.4 M in 84 min at a flow rate of 2.2 mL/min).53
Table 2. Protocol for the Solid-Phase Synthesis of Oligomers a
Steps Time Repetitions
1)CH2C12 (1.0 mL) 1 min 3
2)Trityl Deprotection 1 min 1
4% CHC12CO2H/CH2C12 (0.5 mL)
3)Trityl Deprotection (Repeat) 10 min 1
4% CHC12CO2H/CH2C12 (0.5 mL)
4)CH2C12 (0.5 mL) 1 min 4
5)10% Et3N/CH2C12 (0.5 mL) 1 min 2
6)CH2C12 (0.5 mL) 1 min 2
7)Dimethylacetamide (0.5 mL) 1 min 3
8)Coupling Reaction 24 h 1
(30 innol subunit + 30 jimol Et3N in 150 pa, DMA)
9)Dimethylacetamide (0.5 mL) 1 min 1
10)Capping Sequence 10 min 1
(50 p L Et3N + 50 pi, Ac20 in 0.5 mL DMA)
11)Dimethylacetamide (0.5 mL) 1 min 3
12)Repeat steps 111 for each subunit
a) All steps 25°C except for step 8, which was at 40°C.
Synthesis of hexamers used for biophysical testing (28 and 29). A portion of the
crude hexamer 45 (3.6 mg, 1.27 mop was detritylated with 4% CHC12CO2H/CH2C12
(0.75 mL). After 15 min, 1:1 Et20/hexanes (6 mL) was added to precipitate the
resulting amine salt. Following centrifugation, the supernatant was decanted and the
remaining precipitate was triturated three times with 2:1:1 CH2C12:Et20:hexanes (4 mL
portions) to remove trityl byproducts.54
The resulting amine salt was dried in vacuo for 8 h, was taken up in 0.02 M pH 2.5
phosphate buffer and chromatographed on S-Sepharose, using phosphate buffer (pH
2.5) and a gradient of KC1 (01.4 M in 84 min at a flow rate of 2.2 mL/min). Fractions
24 30 were combined, concentrated to approximately 5 mL, and eluted onto a Waters
Sep-Pak® C18 cartridge.The sample was desalted and neutralized by flushing
successively with 20 mL of H2O, 6 mL of 1% Et3N/H20, and again with 6 mL of H2O.
The free amine product was then eluted off the Cig cartridge by flushing with 80%
CH3CN/H20 (3 x 3 mL). The 80% CH3CN/H20 fractions were combined, CH3CN
was removed under reduced pressure, and the H2O was removed via lyophilization to
afford 83% yield (2.7 mg, 1.05 [mop of the hexamer amine.Pos. FABMS of the
purified hexamer amine revealed a single high molecular weight ion cluster centered at
the expected 2585, corresponding to [M+H]+.
This dried solid was then transferred with DMF (120 'IL) to a Kontes micro V-vial
adapted with a solid-top screw cap and Teflon-faced, styrene-butadiene rubber liner
(pressurization vial), followed by 20 4 of polyethylene glycol monomethyl ether-
derived mixed carbonate 47.23 Et3N (6 4) was added, and the reaction mixture
allowed to stir at RT for 48 h.This reaction mixture was then taken on directly to
ammonolysis by diluting with additional DMF (to a total volume of 1 mL), cooled to
0°C, and followed by addition of cold conc. NH4OH (1 mL). The vial was sealed and
stirred 24 h at 30°C. The reaction mixture was transferred to a round-bottomed flask,
and solvents were removed in vacuo. The tailed, deprotected product was purified by
ion-exchange chromatography on S-Sepharose, using 0.02 M phosphate buffer (pH 2.5)
and a gradient of KC1 (0 - 1.4 M in 84 min at a flow rate of 2.2 mL/min). Fractions
were collected every 1.5 min and the chromatographic profile revealed a major,
symmetrical peak at 3036 min (fractions 2024) corresponding to the desired
hexameric product.55
Fractions 2024 were combined and desalted on chromatographic grade
polypropylene (Polysciences), which had been equilibrated with 100% H2O. The
column was flushed with H2O at a flow rate of 2.2 mL/min for 10.5 min (23.1 mL),
0.5% aq. NH4OH for 6 min (13.2 mL), and again with H2O for an additional 6 min
(13.2 mL). The sample was then eluted with 80% Me0H/H20. The Me0H was
evaporated in vacuo and the remaining aqueous solution was lyophilized to provide
45% yield (1.0 mg, 0.47 .t.mol) of white flocculent solid, 28. The high resolution 1H
NMR of 28 revealed a complex spectrum containing data consistent with the expected
structure including the aromatic region, as evidenced by six nearly distinguishable
cytosine subunits. 1H NMR (300 MHz, DMSO-d6): 5 8.10 (1H, br m), 7.907.35
(10H, m), 7.356.70 (14H, m), 5.82 (1H, d, J = 7.69 Hz), 5.805.50 (5H, m), 4.67
(1H, br t), 4.603.80 (18H, m), 3.753.05 (large envelope containing the PEG protons,
and several signals of the oligomer), 2.97 (3H, s), 2.451.85 (8H, m), 1.851.35 (6H,
m). The crude hexamer composed of subunits with the opposite (S)-configuration (5.0
mg, 1.77 iimol), was converted to 53% yield of hexamer 29 (2.0 mg, 0.93 limo') in an
analogous fashion.
Native DNA [p(dG)6 and the control oligomer, p(dC)6] and RNA (poly G) utilized
for biophysical testing of polyurethanes 28 and 29 (as well as polyamides 56 and 57),
were purchased from Pharmacia and Sigma Chemical Company, respectively.
Hybridization affinities of each hexamer with complementary p(dG)6 and poly G, were
assessed via thermal denaturation experiments in a pH 7.2 low salt buffer consisting of
0.02 M NaOH buffered with 0.2 M H3PO4 to pH 7.2. Stock solutions of the testing
oligomers were prepared by dissolving the oligomers in 80% DMSO/H20. The
concentration of each stock solution was determined by the nearest neighbor group
extinction coefficient method,40 with actual UV spectroscopy measurements of the
diluted stock oligomer solutions. Equimolar amounts of native DNA (or RNA) and test
oligomer were then diluted to 1.00 mL in the test buffer (to a final concentration of 1056
1.1M), warmed, and slowly cooled to insure complete annealing of the hexameric
analogues to their native nucleic acid complements. UV spectra were recorded in
increments of 2°C, monitoring from 9°C to 85°C with 2 min of stabilization time. The
thermal melt curve was obtained by plotting UV absorbance changes at 260 nm (or 275
nm) from the recorded spectra versus temperature. Tm values were obtained via direct
extrapolation from the corresponding thermal melt or from the 1st derivative of the
appropriate thermal denaturation curve.
N-Tr-Valylglycine (50). Valylglycine (0.50 g, 2.87 mmol) and trityl bromide (2.04 g,
6.31 mmol) were dissolved in 2:1 CHC13:DMF (15 mL) and allowed to stir for 40 min
at RT.37 Et3N (1.60 mL, 14.48 mmol) was dissolved in 2:1 CHC13:DMF (3 mL) and
added dropwise over 10 min, and stirring was continued for 90 min at RT. Me0H (15
mL) was added and the reaction mixture was stirred for 30 min at 50°C. Solvents were
removed in vacuo and the residue was triturated thrice with Et20 (20 mL portions).
The resulting residual solid was found however, to be mostly Et3N1-1÷13r, and
consequently, the combined ethereal triturates were diluted with Et20 (to a final volume
of 150 mL) and extracted with 10% aq. citric acid (3 x 50 mL), H2O (2 x 50 mL), and
satd NaC1 (1 x 50 mL). The organic layer was dried over MgSO4 and the solvent was
removed in vacuo. Attempts to recrystallize the crude product were unsuccessful, and
hence, the product was purified on SiO3 2 (1.2515% Me0H/CHC13 with 1% Et3N) to
afford 0.63 g (42% yield) of 50 as a colorless oil. 1H NMR (300 MHz, DMSO-d6): 5
7.507.12 (16H, m), 3.28 (2H, m), 3.102.95 (1H, m), 2.87 (1H, d, J = 8.55 Hz), 1.72
1.56 (1H, m), 0.83 (6H, d, 6.84 Hz).57
N-Tr-Valylglycine activated subunit (51). Compound 50 (30 mg, 0.058 mmol), p-
nitrophenol (40 mg, 0.290 mmol), and predried 1-hydroxybenzotriazole (3 mg, 0.022
mmol) were dissolved in CH2C12 (0.15 mL) and were cooled to 0°C. The 1-(3-
dimethylaminopropy1)-3-ethylcarbodiimide methiodide (52 mg, 0.174 mmol) was
added and the reaction mixture was allowed to stir at 0°C for 30 min and an additional 4
h at RT. The reaction mixture was diluted with CHC13 (30 mL) and extracted with 0.10
M NaOH (5 x 5 mL), pH 7 buffer (1 x 5 mL), and satd NaC1 (1 x 10 mL). The residue
was purified on SiO2 (1.25 - 2.5% Me0H/CHC13) to afford 17 mg (55% yield) of 51 as
a white solid. 1H NMR (300 MHz, DMSO-d6): 8 8.29 (2H, m), 7.93 (1H, t, J =5.21
Hz), 7.507.14 (17H, m), 3.62 (2H, d, J = 5.29 Hz), 3.07 (1H, dd, 9.00, 4.40 Hz), 2.88
(1H, d, J = 9.04 Hz), 1.85 - 1.70 (1H, m), 0.87 (6H, d, J = 6.58 Hz). Pos. FABMS, m/z
(rel. intensity): 538.2 ([M+1-1] +, 0.7), 461.2 (2.5), 460.2 (8.0), 314.2 (4.7), 244.2 (63.5),
243.2 (100.0). HRMS (Pos. FAB): calcd for C32H32N305 [M+H]+ 538.2342, found
538.2344.
N-Tr-Valylglycine benzylamide (52). Compound 50 (30 mg, 0.058 mmol), p-
nitrophenol (40 mg, 0.290 mmol), and predried 1-hydroxybenzotriazole (3 mg, 0.022
mmol) were dissolved in CH2C12 (0.15 mL) and were cooled to 0°C. The 1-(3-
dimethylaminopropy1)-3-ethylcarbodiimide methiodide (52 mg, 0.174 mmol) was
added and the reaction mixture was stirred at 0°C for 30 min and an additional 4 h at
RT. Benzylamine (8 !IL, 0.070 mmol) and Et3N (81 p.L, 0.580 mmol) were added, and
after 8 h at RT the reaction mixture was diluted with CHC13 (50 mL) and extracted with
0.10 M NaOH (5 x 10 mL), pH 7 buffer (1 x 10 mL), and satd NaC1 (1 x 20 mL). The
residue was purified on SiO2 (1.252.5% Me0H/CHC13) to afford 21 mg (72% yield)
of 52 as a white solid. 1H NMR (300 MHz, DMSO-d6): 8 8.11 (1H, t, J = 5.57 Hz),
7.48 (1H, t, 5.00 Hz), 7.467.12 (16H, m), 4.24 (2H, d, J = 5.91 Hz), 3.40 (1H, m),58
3.203.00 (2H, m), 2.90 (1H, d, J = 8.75 Hz), 1.821.68 (1H, m), 0.85 (3H, d, J = 6.74
Hz), 0.84 (3H, d, 6.84 Hz). Pos. FABMS, m/z (rel. intensity): 506.3 ([M+H] +, 2.3),
314.2 (4.7), 244.2 (47.1), 243.2 (100.0). HRMS (Pos. FAB): calcd for C33H35N302
[M+H]+ 506.2807, found 506.2806.
N- Trityl- [valylglycine]2 benzylamide (53). Compound 52 (8 mg, 0.0158 mmol) was
reacted with 5% C12HCCO3H/CH3C13 (0.50 mL) for 15 min at RT. The amine salt was
precipitated with 1:1 Et20:hexanes (3 mL), and the solid was then triturated twice with
1:1 Et20:hexanes (3 mL portions). The amine salt was dissolved in dimethylacetamide
(0.10 mL), Et3N (14 pt, 0.102 mmol) was added, followed by the addition of
compound 51 (11 mg, 0.0204 mmol). The reaction mixture was then allowed to stir for
8 h at RT. Solvents were removed in vacuo and the residue was purified on Si02 (1.25
- 5% Me0H/CHC13) toafford 5 mg (74% yield) of 53 as a white solid. 1H NMR (300
MHz, DMSO-d6): 8 8.26 (2H, m), 7.65 (1H, d, J = 8.14 Hz), 7.52 - 7.12 (22H, m), 4.36
- 4.18 (2H, m),4.09 (1H, t, J = 7.30 Hz), 3.833.63 (2H, m), 3.50 - 3.38 (2H, m), 3.14
2.96 (2H, m), 2.90 (1H, d, J = 8.57 Hz), 2.001.86 (1H, m), 1.84 - 1.68 (1H, m), 0.83
(12H, m). Pos. FABMS, m/z (rel. intensity): 662.4 ([M+11]±, 2.4), 584.3 (1.6), 244.2
(21.1), 243.2 (100.0). HRMS (Pos. FAB): calcd for C40H48N504 [M+H]l- 662.3706,
found 662.3710.
N-CBZ-Alanyl subunit benzylamide (54). Compound 38 (40 mg, 0.081 mmol) and
pentafluorophenol (75 mg, 0.410 mmol) were dissolved in DMF (0.5 mL) and cooled to
0°C. The 1-( 3- dimethylaminopropyl )- 3- ethylcarbodiimide methiodide (60 mg, 0.203
mmol) was added, and the reaction mixture was stirred 4 h while gradually warming to
RT. Benzylamine (12 pt, 0.113 mmol) and Et3N (113 1.1.L, 0.810 mmol) were added
and the reaction mixture was allowed to stir an additional 8 h at RT. Solvents were59
removed in vacuo and the residue was dissolved in CHC13 (20 mL) and extracted with
H2O (1 x 5 mL), 0.15 M NaOH (3 x 5 mL), and satd NaC1 (1 x 10 mL). The organic
layer was dried over MgSO4 and solvents were removed under reduced pressure. The
product was purified on Si02 (1.252.5% Me0H/CHC13) to afford 34 mg (72% yield)
of 54 as a white solid. 1H NMR (300 MHz, DMSO-d6): 8 11.11 (1H, s), 8.71 (1H, m),
7.98 (2H, d, J = 8.44 Hz), 7.91 (1H, d, J = 7.21 Hz), 7.69 (1H, m), 7.55 (2H, d, J = 8.54
Hz), 7.507.14 (11H, m), 4.99 (2H, ABq, JAB = 12.79 Hz, AvAB = 30.54 Hz), 4.66
4.52 (1H, m), 4.45 - 4.33 (1H, m), 4.29 (2H, d, J = 5.87 Hz), 3.873.74 (1H, m), 1.32
(9H, s). Pos. FABMS, ink (rel. intensity): 583.1 (30.6), 582.1 ([M+H]+, 76.5), 386.2
(15.3), 238.1 (27.1), 161.1 (87.1), 91.1 (54.1), 85.1 (100.0). HRMS (Pos. FAB): calcd
for C33H36N505 [M+H]+ 582.2716, found 582.2716.
N-BOC-Glycylalanine-derived subunit benzylamide (55). Compound 54 (10.0 mg,
0.0172 mmol) was dissolved in HBrI-10Ac (0.50 mL) and stirred for 15 min at RT.
Anhydrous Et20 (4 mL) was added to precipitate the amine salt, which was
subsequently centrifuged and triturated twice with additional anhydrous Et20 (4 mL
portions). The amine salt was dissolved in DMF (0.10 mL), Et3N (24 pL, 0.172 mmol)
was added, followed by the addition of N-BOC-glycine p-nitrophenyl ester(5.6 mg,
0.0189 mmol). After stirring for 16 h at RT, the solvents were removed in vacuo. The
residue was dissolved in CHC13 (20 mL) and extracted with H2O (1 x 5 mL), 0.15 M
NaOH (3 x 5 mL), and satd NaC1 (1 x 10 mL). The organic layer was dried over
MgSO4 and solvents were removed under reduced pressure. The product was purified
on Si02 (1.25 - 2.5% Me0H/CHC13) toafford 8.0 mg (77% yield) of 55 as a white
solid. 1H NMR (300 MHz, DMSO-d6): 6 11.07 (1H, s), 8.57 (1H, br m), 8.26 (1H, br
m), 7.96 (2H, d, J = 8.37 Hz), 7.87 (1H, d, J = 7.45 Hz), 7.53 (2H, d, J = 8.46 Hz), 7.35
- 7.15 (6H, m),7.01 (1H, br m), 4.844.72 (1H, m), 4.404.20 (3H, m with 2H, d, J =60
5.28 Hz at 4.28), 3.973.83 (1H, m), 3.65 - 3.45 (2H, m), 1.35 (9H, s), 1.31 (9H, s).
Pos. FABMS, miz (rel. intensity): 606.3 (30.6), 605.3 ([M+H] ±, 82.4), 594.4 (35.3),
272.1 (20.0), 161.1 (100.0), 91.1 (21.4), 77.1 (21.2), 57.1 (15.3). HRMS (Pos. FAB):
calcd for C32H41N606 [M+11]± 605.3087, found 605.3085.61
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VI. APPENDIX
Chemical Abstracts Names for Key Compounds
(21).Ethanol, 2-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]ethoxy]-
(22).1,2-Pyrrolidinedicarboxylic acid, 1-(9H-fluoren-9-ylmethyl) 24242-[[(4-
methoxyphenyediphenylmethyl]amino]ethoxy]ethyl] ester
(23).1,2- Pyrrolidinedicarboxylicacid, 4-hydroxy-, 2-(4-nitrophenyl) 142-
(phenylsulfonyl)ethyl] ester
(24).DL-Proline, 1-[4-hydroxy-1-[[2-(phenylsulfonyeethoxy]carbony1]-DL-proly1]-,
2-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]ethoxy]ethyl ester
(25).DL-Proline, 114- [ [ (4- nitrophenoxy)carbonyl] ox y] - 1[ [2- (phenylsulfonyl)
ethoxy] carbonyl] -DL-prolyl] -,2- [2- [[(4-methoxyphenyl)diphenylmethyl] amino]ethoxy]
ethyl ester
(30).3-Oxazolidinecarboxylic acid, 4-[(4-amino-2-oxo-1(2H)-pyrimidinyl)methy1]-
2,2-dimethyl-, 1,1-dimethylethyl ester, (R)-
(34).3-Oxazolidinecarboxylic acid, 2,2-dimethy1-4-[[4-[[4-(4-morpholinylmethyl)
benzoyl] amino]-2-oxo-1(2H)-pyrimidinyl]methyll-, 1,1-dimethylethyl ester, (R)-
(35).Benzamide, N-[ 1,2-dihydro-1- [3-hydroxy-2-[(triphenylmethyl)amino]propy1]-2-
oxo-4-pyrimidiny1]-4-(4-morpholinylmethyl)-, (R)-65
(10).Carbonic acid, 3444[4-(4-morpholinylmethyl)benzoyl]amino]-2-oxo-1(2H)-
pyrimidinyl]-2-[(triphenylmethypamino]propyl 4-nitrophenyl ester, (R)-
(36).3-Oxazolidinecarboxylic acid, 4-[[4-[[4-(1,1-dimethylethyl)benzoyl]amino]-2-
oxo-1(2H)-pyrimidinyl]methy1]-2,2-dimethyl-, 1,1-dimethylethyl ester, (R)-
(37).Carbamic acid, [2-[4-[[4-(1,1-dimethylethyl)benzoyl]amino]-2-oxo-1(2H)-
pyrimidiny1]-1-(hydroxymethypethy1]-, phenylmethyl ester, (R)-
(38).1(2H)-Pyrimidinepropanoic acid, 44[4-(1,1-dimethylethypbenzoyl]amino]-2-
oxo-a-[{(phenylmethoxy)carbonyllaminok, (R)-
(39).Glycine, N-[344-[[4-(1,1-dimethylethyl)benzoyl]aminol-2-oxo-1(2H)-
pyrimidinyl]-N-[(phenylmethoxy)carbonyl]-D-a1anyl]-, 1,1-dimethylethyl ester
(40).Glycine, N4314-[[4-(4-morpholinylmethyl)benzoyl]amino]-2-oxo- 1(2H)-
pyrimidiny1]-N-{ (phenylmethoxy)carbony1]-D-alanyl]-, 1,1-dimethylethyl ester
(12).Glycine, N-[3-[4-[[4-(4-morpholinylmethyl)benzoyl]amino-2-oxo-1(2H)-
pyrimidiny1]-N- (triphenylmethyl)-D-alany1]-, 4-nitrophenyl ester